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Polyvinylpyrrolidone (PVP) is probably one of the most utilized pharmaceutical polymers with 
applications ranging from blood plasma substitute to nanoparticle drug delivery since its synthesis in 
1938. It is a highly biocompatible, non-toxic and transparent film-forming polymer. Although high 
solubility of PVP in an aqueous environment is advantageous, it still poses several problems for some 
applications in which sustained targeting and release are needed, or hydrophobic drug inclusion and 
delivery systems are to be designed. For this reason, in the field of controlled drug release, it is often 
used as an additive and not as a protagonist. On the other hand, in case of wound treatment, PVP can be 
a suitable biopolymer for the design of wound dressings due to its capacity to inhibit the crystallinity of 
several drugs, opening to their topical application, and its adhesive properties to the skin.  
Therefore, the main goal of this Ph.D. was to demonstrate that this underestimated synthetic polymer 
can be a proper based material for the design, the fabrication and the formulation of new smart wound 
dressings for the delivery of antibiotic and antioxidant compounds. 
In the first part of this Ph.D. study, PVP and acetic acid (AcOH) were used to inhibit the crystallization 
of the antibiotic Ciprofloxacin (Cipro) and to prepare transparent PVP foils as well as nanofiber mats. 
The presence of the antibiotic and the acid inside of the PVP matrix caused a plasticizer effect of these 
ingredients in the final mechanical properties of the films. Both films and nanofibers were able to 
release the Cipro, and an antibacterial synergism between acetic acid and the antibiotic were 
highlighted in vitro antibacterial assay. The PVP/Cipro/AcOH materials showed biocompatibility and a 
different rate of resorption in an in vivo wound mice model. In the second part of the Ph.D., a 
multifunctional polyvinylpyrrolidone/hyaluronic acid-based bilayer construct for sequential delivery of 
cutaneous antiseptic and antibiotic was designed and fabricated by using two scalable methodologies. 
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The bilayer material showed strong adhesion to skin, effective antibacterial activity against three 
strains, biocompatibility, hemocompatibility, anti-inflammatory properties both in vitro and in vivo, 
resorption by the skin and accelerate the wound closure in mice model. Then, the PVP/Cipro/AcOH 
films and nanofibers were further characterized on an infected wound model based on ex-vivo human 
skin. The materials resulted non-toxic and with suitable profiles of the release of Cipro inside of the 
skin. Moreover, they highlighted a strong antibacterial activity against biofilms infection of 
Pseudomonas aeruginosa and, especially, in case of the films they were able to eradicate completely 
the biofilms from the skin.  
Finally, PVP was combined with the dietary phenolic compounds, p-coumaric acid (PCA). The 
introduction of the PCA in transparent films led to an increase of the hydrophobicity of the PVP-based 
matrix. Indeed, changes in water contact angles, water uptake and the rate of dissolution in water were 
found. Furthermore, the new biocomposites were investigated as drug delivery system of two model 
drugs and their antioxidant and anti-inflammatory activity were analyzed in vitro and in vivo, 
respectively. 
In conclusions, several PVP-based wound dressings were designed and fabricated, demonstrating their 
potential efficacy for the treatment of infected wounds, burns, and chronic wounds.        
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1.1 History, synthesis, and applications of Polyvinylpyrrolidone 
Poly(vinylpyrrolidone) (PVP), also known as polyvidone or povidone, was synthesized for the first 
time in 1938 by the chemist Walter Reppe. The first step of the fabrication of the PVP was to 
synthesize its monomer N-vinylpyrrolidone starting from the main component acetylene and 
formaldehyde in the presence of ammonia. Then, the monomer was polymerized via radical reaction 
using hydrogen peroxide as catalyst [1].   
Nowadays, this synthetic polymer is employed in numerous medical and nonmedical fields such as 
pharmaceutical industry and medicine [2-4], optical and electrical applications [5-7], membranes [8], 
adhesives [9], ceramics [10], paper [11], coatings and inks [12], lithography and photography [13], 
fibers and textiles [14, 15], and environmental applications [16, 17]. By the way, pharmaceutical and 
biomedical are the first and probably the most recognized fields of application of PVP due to its 
excellent biocompatibility, the capability to form stable association compounds and complexes with 
many active compounds, chemical stability, solubility in water and many organic solvents as well as 
low cost and accessibility [18].  
Historically, PVP was the first polymer used during World War II as a blood plasma substitute and 
expander for trauma victims [3, 19]. In the present, it is mostly used as a binder in the table 
manufacturing for oral administration due to its high solubility in an aqueous environment. Binder has 
the role in holding all ingredients together till the tablet reaches the stomach and then it quickly 
dissolves to release the drug [2]. Moreover, several studies demonstrated how oral administration of 
PVP is completely safe for the body due to its particles sizes 1-100 nm that can dissolve rapidly and 
completely through the kidney [18]. Furthermore, PVP at the low molecular weight is considered safe 
also if administrated by intraperitoneal, intramuscular, and intravenous routes [20]. The synthetic 
polymer has also been proved to be non- irritating for eyes or skin, for this reason, it is also broadly 
applied for the fabrication of contact lens and cosmetic products [21-23].  
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In the formulation field, PVP has been appreciated for its capacity to enhance the solubility and the 
dispersion of low soluble hydrophobic drugs in water such as ketoconazole, flunarizine, and curcumin 
[24-26]. Moreover, as Mora-Huertas et al. reported in their review, PVP can be used as additive and 
stabilizer for emulsions and nanocapsules [27].  
Due to its chemical structure, PVP can establish interactions of different nature and form stable 
complexes with several small molecules as well as with many polymers [28, 29]. For instance, in 1995 
H.A. Shelanski and M. V. Shelanski, two researchers of the Industrial Toxicology Laboratories in 
Philadelphia discovered the most famous complex of PVP that is the topical disinfectant povidone-
iodine (PVP-I) [30]. This product is currently on the market with the name of Betadine, Pyodine or 
Wokadine and has been demonstrated efficacy against several common infective skin bacterial strains 
such as Staphylococcus aureus, Escherichia coli and Pseudomonas aeruginosa [31]. PVPI can further 
be processed as beads [32], incorporated in alginate-based films [33], or combined with gelatin to form 
bilayer cryogels [34].  
Numerous drugs present a high level of crystallinity, and this can negatively affect their administration, 
delivery, and absorption [35]. Jain and Banga [36] studied various additives to inhibit crystallization of 
two model drugs, and PVP  was found to be the most effective allowing the incorporation of both drugs 
in amounts higher than their respective saturation solubility in transdermal drug delivery systems. 
Furthermore, Taylor and Zografi [37] imputed PVP capacity to break the crystallinity of indomethacin 
due to its amide group that can establish strong H-bonds with the carboxylic group of the drug.    
PVP can also form dried films that result fully transparent but highly fragile and rigid and, for this 
reason, required the addition of a plasticizer [38, 39]. Finally, it is also used in the field of the 
electrospinning as enhancer agent of the process due to its capacity to adjust the viscosity and the 




1.2 Polyvinylpyrrolidone and drug delivery systems  
In these years, research moved toward the fabrication of effective devices for delivering and controlling 
the release of drugs. For instance, several scaffolds, implants, stents, nanoparticles, nanocapsules, 
tablets, nanofibers, hydrogels, and films were designed and functionalized to resist inside of the body 
for many years and ensuring a slower and controlled release of the loaded-drug [41]. Among this jungle 
of systems, PVP often played the role of simple additive, dispersive or stabilizer, due mainly to its high 
solubility in water and, consequentially, fast dissolution in the internal body fluids [2, 3]. Pure PVP-
based systems are rare and often underestimated in literature.  
Therefore, to obtain the role of the main character in the great theater of the delivery and control of 
drugs release, and to overcome the drawback of the fast solubilization in water, PVP has been 
crosslinked or copolymerized with other macromolecules. The crosslinking of the pure polymer can be 
achieved by radical or thermal reaction leading to the formation of strong hydrogels [42-45]. In 
addition, PVP has been introduced in different copolymer chains reacting with various synthetic and 
natural polymers such as polyvinyl alcohol, polycaprolactone, silk, k-carrageenan, and chitosan [46-
53]. 
Although systems that are able to remain insoluble in the human body for a long time are often a 
desirable feature in order to obtain a slow release of drug and avoid the peak of the drug in the blood, in 
some biomedical applications, instead, a burst release can be the best choice.  
For instance, the new formulation Okitask® is composed of granules, and it was designed for the 
treatment of an occasional headache to have an immediate release and absorption of anti-inflammatory 
by sublingual route. Thus, the anti-inflammatory drug can reach faster the brain and minimizing the 
collateral effect of these drugs into the gastrointestinal tract [54].  
Instead, in the case of wounds or burns, the delivery times are more complicated. Indeed, if the system 
is not easily resorbed by the skin, it can hinder the repair process and create intense discomfort in the 
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patient but, at the same time, the polymeric system should be able to swell and release a high quantity 
of drug in situ, especially in case of bacterial/biofilms infection [55, 56]. Therefore, a suitable drug 
delivery system for wound treatment should have a timescale of its life in the wound bed of some days.  
As described before, PVP showed high biocompatibility, miscibility with several solvents, polymers, 
and drugs as well as the possibility of forming transparent films and electrospun nanofibers. Its high 
sensitivity to interact with small molecules through H-bonds or complexation could be used to regulate 
the degradation rate in an aqueous medium. In addition, several drugs present a high level of 
crystallinity preventing their topical application and forcing an oral administration. Consequently, PVP 
could help to deliver drugs directly into the wounds due to its capacity to inhibit the crystallization of 
drugs. Finally, PVP has also been used as an adhesive agent to different surface including the skin[57].  
Therefore, PVP looks like an underestimated but suitable candidate for the fabrication of new wound 
dressing materials.   
 
1.3 Evolution and design parameters for smart wound dressings 
Wound dressings have been evolving steadily in close conjunction with recent trends and advances in 
bio-based polymer synthesis, and processing micro/nanotechnologies [58, 59]. Dressings grew from 
materials or tapes that simply covered and concealed the wound, to materials that can interact with 
wounds so that important wound healing factors such as moisture management, active ingredient 
delivery and interaction with cells or proteins can be tuned or enhanced in situ. For chronic non-healing 
wounds or burns, for instance, one of the most important aspects is to prevent infection, as discussed 
above. As such, dressings should act as a shield protecting the wound area and, at the same time, 
provide a continuous or sustained release of an antiseptic agent at the wound surface to ensure a long-
lasting antimicrobial action in combination with the maintenance of a physiologically moist 
environment for healing (Figure 1.1) [60, 61]. Moreover, in case of bacterial infections, the application 
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of antimicrobial wound dressing is a suitable strategy to avoid massive and prolonged oral 
administration of antibiotic that can create collateral effects on the patients and resistance by the 
bacteria. 
 
Figure 1.1 Schematic representation of the advantages in the healing process of an antibacterial wound 
dressing is applied to the top of a wound. (Figure adapted from Simões et al. 2018 [61]). 
 
Regardless of the choice of the adequate strategy to treat an injured skin is also affected by several 
wound features, such as type (acute, chronical, burn, excision), depth (superficial, full-thickness), the 
quantity of exudate, color, shape, and location within the body [62, 63]. Likewise, the selection of the 
right formulation regarding polymers and bioactive agents as well as the solvent of production can 
affect the final quality and cost of the wound dressing.  
Considering the different strategies nowadays proposed, wound dressing devices can be divided into 
traditional, modern, bioactive, and skin substitutes [62]. Among the traditional dressings, soaked 
gauzes [64, 65], bandages or cotton wool [66] can be counted, which are relatively cost-effective and 
can serve as a primary treatment to cover the injured skin. However, the excessive absorption of 
exudate does not provide the necessary moisture onto the wound bed, ultimately crucial for the 
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restoration of the physiological conditions [60]. Hydrogels, films, nanofibers, and foams based on 
synthetic polymers, such as polyvinyl alcohol, polyethylene glycol, and PVP, are categorized as 
modern dressings [49, 67-69]. Wound dressings in the form of hydrogels tend to be transparent with 
many advantages such as flexibility, deterioration resistance as the wound fluids are absorbed 
permitting clean and neat removal of the wound dressing upon healing or during replacement, among 
others. Researchers are continuously developing new hydrogel wound dressings in order to address a 
number of gel related shortcomings, such as the need for a secondary dressing, dehydration in time, 
securing on the wound properly, and initiation of peri-wound maceration [70]. Flexible, water vapor 
permeable, self-adhering and polymeric thin film wound dressings are equally popular and generally 
classified as interactive and bioactive dressings [71, 72] compared to traditional passive dressings like 
gauze and tulle products that account for the largest market segment today [73]. Nanofibers produced 
by means of electrospinning methods are another interesting technology for wound dressing 
fabrication. The main advantages of this system are associated with their 3D structure and porosity, 
useful to accelerate the healing process. On the other hand, the manufacture of nanofibers often 
requires the use of organic and toxic additives and not all polymers can be easily electrospun. Bioactive 
dressings are composed of naturally-derived, biocompatible and biodegradable materials, such as 
collagen [65, 74], hyaluronic acid [75, 76], chitosan [77, 78], silk fibroin [79, 80], bovine serum 
albumin [81, 82], and alginate [83, 84]. As structural molecules of the extracellular matrix (ECM), 
collagen and hyaluronic acid can exploit active functions during the healing process [85]. Finally, 




 [87] and TransCyte
®
 [88], have been 
accounted for their high efficacy, especially in the case of burns or chronic wounds. However, those 
constructs may present severe limitations, related to poor adhesion onto the wound bed, difficult 
removal of the artificial extracellular matrix, and lack of active agents against bacteria, which makes 
them prone to infections [63, 86, 87, 89, 90].   
10 
 
As such, an intelligent wound dressing should minimize the aforementioned negative environmental 
effects but also help accelerate the healing process without causing discomfort or needing frequent 
replacement [59].  
Therefore, development of new, inexpensive and intelligent polymeric wound dressings from 
biodegradable polymers that can ensure effective protection and elimination of bacterial colonizing the 
wound, as well as sustaining the regeneration of new tissue is a relevant multidisciplinary challenge for 
medicine, pharmacology,  microbiology, chemistry, and material science.  
 
1.4 Films and nanofibers dressings 
This challenge can be partially addressed by choice of the fabrication method of the dressing material 
and its properties, such as porosity, transparency, flexibility and 3D structure [91-94].  
Polymeric films constitute one of the most appropriate therapeutic approaches for the topical 
administration of drugs. They can help in overcoming low solubility drawbacks of drugs in water, 
allowing delivery in situ of high concentration of drugs, and generating more prolonged effects [95]. 
The topical application minimizes the systemic adverse effects caused by drug absorption or the use of 
high levels of drug concentration dispersed throughout the body. Films can be prepared by various 
methods such as film solvent casting or evaporation, compression moldings, roll milling, and spin 
coating. These methods can exhibit and ensure differences in reproducibility of thickness, uniformity, 
and cost of the film.  
Nanofibers mats are another interesting type of dressing that can ensure good-performance for wounds 
application. They are produced by using the electrospinning process. An ordinary electrospinning setup 
is composed of a polymer solution, a syringe, a power source, a collector or target, and a syringe pump. 
The main forces behind the generation of nanofibers are electrostatic forces [96]. Indeed, a high 
electrical potential is applied between the needle and the collector creating a ions migration in the 
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solution. First, the polymer solution remains at the tip of the needle due to surface tension. As the 
electrical potential increases, the hemispherical surface of the polymer solution elongates to form a 
conical shape, called Taylor cone, at the needle tip [97]. A further enhancement of the electrical field 
pushes the system towards a critical value, leading to the formation of a polymer jet when the repulsive 
electrostatic force overcomes the surface tension. At this point, a polymer jet is ejected from the tip of 
the Taylor cone, and it moves straight towards the metal collector. The jet undergoes a series of 
electrically driven bending instabilities, develops into a series of loops expanding and gradually thins in 
the air due to elongation before reaching the collector. During the jet movement, the solvent 
evaporates, and the charged jet is accumulated on a collector and becomes nanofibers [98].  
The final material is characterized by nanometric size, high porosity, and surface area and a random 3D 
structure.  
Electrospun nanofibers are mainly used for the design of scaffolds due to their 3D structure similar to 
the 3D structure of ECM in the skin. Indeed, this morphology represents a useful stimulus for the 
proliferation and the attachment of cells, improving the healing rate. Moreover, The final porosity and 
high surface-area allow also obtaining a material with good breathability, an important parameter to 
achieve a successful repair process [99].  Finally, electrospinning can be considered a good method for 
entrapping in polymeric matrices drugs, with low solubility in water solvent and tuning the release rate 
[100]. 
 
1.5 Wound repair: a complex mechanism with a major financial 
burden 
Skin, our largest organ in the human body, constitutes the primary barrier against the environment and 
bacterial, fungal and viruses infection but also it plays a key role in the thermoregulation of the body 
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and can produce and secrete sebum and sweat. It is usually colonized by lactic acid bacteria (LAB), 
which contribute to keeping its partially acid pH [101]. On the other hand, skin can also release 
antibacterial compounds such as lysozyme and cationic antimicrobial peptides (CAMPs) [102, 103] 
useful for the self-cleaning of the organ. Skin is mainly composed of three regions called epidermis, 
dermis, and hypodermis, each one of them possessing specific biological and structural functions [104].  
Cutaneous injuries are broadly diffused in our daily lives. They can either be in the form of simple 
scratches, cuts, and sunburns, or as large or deep wounds caused by various accidents as well as 
surgical interventions or radiation. In the case of skin lesion, every its single region can undergo 
damage and can partially or totally lose its functionalities, depending on the severity of the injury 
[105]. Consequently, after injuries, the body initiates a process of wound healing, which is a dynamic 
and complex cascade of highly integrated and overlapping events, such as hemostasis (0 h after the 
injury), inflammation (1-3 days), proliferation (4-21 days), and remodeling (21 days – 1 year) [106, 
107].  
Immediately after skin damage, components of the coagulation cascade, inflammatory pathways, and 
immune system are activated to prevent excessive fluid and blood losses and to clean the wound bed 
from the dead and devitalized tissues and bacteria [104]. Hemostasis is characterized by the formation 
of a platelet plug and then of a fibrin matrix, which has the role of scaffold for infiltrating cells [108]. 
Neutrophils appear first in the wound area due to their high concentration in the blood circulation and 
response to the activation of complement, the degranulation of platelets and the products of bacterial 
degradation [105, 109] (Figure 1.2A). Neutrophils have three main tasks: generates free radicals to kill 
bacteria; releases proteases, such as matrix metalloproteinase (MMP)-2 and -9 and serine proteases, to 
digest the collagen; phagocytize bacteria and matrix debris [110, 111]. Monocytes arrive after 2–3 day, 
and undergo differentiation into macrophages. Macrophages can produce and secrete some growth 
factors, such as interleukin 1 (IL-1) and transforming growth factors alfa and beta (TGF-α and TGF-β), 
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and can play a crucial role for coordinating later events in response to injury [112]. On the other hand, 
it has been reported in different studies that an excess of the immune response is not always a benefit 
for the repair, and even that healing can be faster with less inflammatory cells, especially if the 
bacterial infection is prevented [113, 114]. Moreover, it has been also demonstrated that the repair 
process can still occur also in case of absence of neutrophils and macrophages [113, 115].   
The proliferation phase of wound repair occurs 4–21 days after injury and is characterized by cellular 
proliferation and migration of different cell types. The first event is the migration of keratinocytes over 
the injured dermis. They can proliferate, mature and restore the barrier function of the epithelium 
(Figure 1.2B). At the same time, the formation of new blood vessels, called angiogenesis, is triggered 
and regulated by different mediators such as the vascular endothelial growth factor A (VEGFA) and the 
fibroblast growth factor 2 (FGF2; also known as bFGF) [116, 117].  In the later part of this phase, 
fibroblasts appear and stimulated by macrophages, can differentiate into myofibroblasts. 
Myofibroblasts are contractile cells with the function to bring the edges of a wound together. Then, 
these two types of cell are involved together in the production of the extracellular matrix (ECM). This 
latter is mainly composed of collagen and forms the final bulk of the mature scar [118]. The 
remodeling phase of wound repair begins 2–3 weeks after injury and lasts for a year or more. During 
this stage, all of the processes activated after injury wind down and ceased. For instance, the 
endothelial cells, macrophages, and myofibroblasts undergo apoptosis or exit from the wound, leaving 
a mass that contains few cells and consists mostly of collagen and other extracellular-matrix proteins 
(Figure 1.2C). During this long period the collagen is remodeled but, anyway, the tissue never regains 
the same functionality of uninjured skin [119, 120]. 
The skin healing ability can be deeply altered under the presence of certain conditions, such as 
infections, hypoxia, poor blood supply, medications, diabetes mellitus, and vast skin loss [121, 122]. In 
addition, healing remains a gradual process, that extends for several days before new tissue formation 
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is completed (21 days). In case of burns and chronic wounds, this time can be prolonged, increasing, 
even more, the possibility of bacterial infections. Indeed, during this period, the total absence of skin 
coverage and exudate production represent a perfect medium for bacterial growth, leading to a high risk 
of infections for the patients [123].  
 
Figure 1.2 Schematic representation of the main phases of the wound healing process: inflammation 
(A), proliferation (B), remodeling (C). (Figure adapted from Gurtner et al. 2008 [107]). 
 
Chronic wounds formation are rare in healthy individuals. Instead, they are generally associated with 
underlying pathological alteration, for instance, diabetes and obesity that lead to non-healing permanent 
status. In this particular condition, the repair process is not able to advance from the inflammatory to 
the proliferation phase. Therefore, the wound bed environment is characterized by high level of pro-
inflammatory agents and destructive enzymes like MMPs, interleukins, tumor necrosis factor-α (TNF-
α), and free radicals due to an abundant neutrophil infiltration [124]. Moreover, alteration of the 
immune response and impaired levels of growth and angiogenetic factors, such as vascular endothelial 
growth factor (VEGF) and platelet-derived growth factor (PDGF) contribute to holding on the wound 
in the non-healing status.  
At the same time, bacterial infections can support and heighten the chronic process [125]. Indeed, 
Staphylococcus aureus can secrete a protein able to inhibit neutrophil and monocyte chemotaxis [126, 
127]. Similarly, the Gram-negative Pseudomonas aeruginosa can release both extracellular protease, 
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which can digest the collagen and use it as a source of nutrients, and serine protease, which can degrade 
cytokines, leading to an alteration of the patient inflammatory response [128-130]. Furthermore, 
several pathogens can create huge colonies and stick together, forming biofilms, which are microbial 
masses surrounded by a polymeric matrix. This matrix has the function to protect the bacteria by the 
killing activity of antibiotics and patient effectors. Therefore, biofilms can be considered as a physical 
and a biochemical obstruction to wound healing [131]. 
Consequently, the treatment of acute and chronic wounds results still a great and required challenge for 
science and researchers. 
Moreover, taking into account this complex scenario should not upset if the management of wound 
repairing can be considered an immense social and financial burden for society. Indeed, in the UK, the 
actual burden related to wound care management has been estimated to reach £5.3 billion only 
throughout two years (2012/2013). This impressive result arises from the annual cost to manage both 
healed (£2.1 billion) and unhealed (£3.2 billion) wounds. Moreover, as revealed by Chandan et al. in 
2010, in the US 6.5 million patients were affected by chronic wounds with an annual cost of US$25 
billion. While in the Scandinavian countries the cost associated with the wound treatment is around 2-
4% of the total health care expenses.  
These studies strikingly pointed out how, in order to reduce the high costs associated with wound 
managing, a great effort needs to be put towards the implementation of new technologies, aiming to 
facilitate medical procedures and increase the wound treatment success rate [132].  
Science and researchers are still spending time and funding on the design and fabrication of new 
effective medical treatments, such as wound dressings, driven by the fact that this silent and hidden 




1.6 Design and Fabrication of PVP-based Materials as New Wound 
Dressings 
For the design and the fabrication of a wound dressing several considerations has to be taken into 
account, including choice of materials and solvents, their 3D structure, biodegradability, bioactivity, 
bio-resorption and mechanical properties as well as the cost of production. Indeed, this Ph.D. project 
intended to demonstrate that materials based on the synthetic polymer polyvinylpyrrolidone can be a 
suitable and economical choice for the production of new smart wound dressings. Furthermore, PVP 
allows incorporation of hydrophilic and hydrophobic molecules, and it can be easily mixed with 
another biopolymer, starting from eco-friendly solvents. 
Therefore, the main goal of this Ph.D. thesis was to design low-cost and innovative multifunctional 
bioactive PVP-based materials exploiting the film and electrospun nanofibers methods for wound 
healing application.  
Specifically, in chapter 2 of this Ph.D. study will be discussed how to formulate and fabricate fully-
transparent and flexible films and nanofibers mats with antimicrobial activity based on PVP. In chapter 
3 will be presented the scalable fabrication of a multifunctional bilayer construct and its bioactive 
features in-vitro and in-vivo. In the chapter 4 will be examined the toxicity, the drug release and 
diffusion into the skin and the efficacy against Pseudomonas aeruginosa of the films and the 
nanofibers on an infected-wound model based on ex-vivo human skin. Finally, in chapter 5 will be 
debated the production of a new class of bio-composites, based on PVP and a phenolic compound, and 






Chapter 2 : Transparent films 




2.1 Ciprofloxacin and vinegar: a synergic recipe for antibacterial 
transparent films and nanofibers  
Most commercially available wound dressings are frequently opaque. Visual observation of the healing 
process is therefore prevented. Infection or other complications cannot be easily detected with opaque 
coverings. During the inspection, dressing removal generally causes discomfort but also healing 
disruption, bleeding and granuloma formation. Therefore, transparent wound dressings would be highly 
appropriate. Particularly, antiseptic loaded and adhesive free transparent wound dressings that can be 
easily absorbed by the wound are highly desirable in the sense that instead of removal and replacement, 
an identical self-adhering transparent dressing can be immediately applied after the absorption of the 
previous one [134].  
Ciprofloxacin (Cipro) is an antibiotic that belongs to the family of fluoroquinolones [135]. It is 
considered to be one of the most important medications for basic health care [136]. Its spectrum of 
activity includes most strains of bacterial pathogens responsible for respiratory, urinary tract, 
gastrointestinal, and abdominal infections, including gram-negative and gram-positive bacterial 
pathogens [135, 137, 138]. It functions by inhibiting DNA gyrase and topoisomerase IV (type II 
topoisomerases), necessary to separate bacterial DNA, thereby inhibiting cell division. The main 
drawback of monohydrochloride monohydrate-free Cipro is its insolubility in water at physiological pH 
levels of 7.4 [139]. This is due to its molecular structure in dry powder form [140]. As illustrated in 
Figure 2.1, the stable molecular structure of Cipro is a zwitterionic state, in which a positive charge on 
secondary amine of the piperazine ring and a negative charge on the carboxylic group are present [141, 
142]. Strong intermolecular interactions between these charges cause insolubility when dispersed in 
water. To solubilize Cipro in water, it is necessary to reduce the pH disrupting the charge balance of the 




Figure 2.1 Zwitterionic structure of Ciprofloxacin. 
 
Although frequently referred to as Cipro, the most common form of Ciprofloxacin is 
monohydrochloride monohydrate salt tablets (CiproHCl). Both Cipro and CiproHCl are not film-
forming molecules. Upon solution casting from suitable aqueous solvents both tend to crystallize into 
large needle-like shapes (see Figure 2.2A) during solvent evaporation [140, 141, 143-146]. This is 
regarded as one of the main limitations of producing transparent polymeric films loaded with Cipro or 
CiproHCl suitable for biomedical applications [147, 148].  
AcOH was chosen because it is a weak digestible acid (up to 20% in vinegar) and it is commonly used 
in the wound healing field. Usually, it is directly applied to infected burns and wounds, in the form of 
1-5% (v/v) solution in water [149, 150]. Its antibacterial effect is not only due to its acidity but mostly 
due to its capacity to cross the bacterial membrane and change the pH of the cytoplasm [151, 152], 
altering the cellular proton gradients, unfolding protein and causing DNA damages [151]. Furthermore, 
acetic acid is capable of preventing the formation of biofilms and affecting the viability of grown ones 
[153] in addition to its effectiveness against various bacteria including Escherichia coli, 
Staphylococcus aureus, Acinetobacter baumannii [153]. The most significant target of acetic acid is 
Pseudomonas aeruginosa [150] bacterium that generally infects burns [154] and can become resistant 
against fluoroquinolones antibiotics like Cipro [155, 156]. Therefore, the combination of these two 
active agents can result in a good strategy against cutaneous bacterial infections. 
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In this chapter, a facile water-based process to incorporate monohydrochloride monohydrate-free Cipro 
in PVP by using aqueous acetic acid (AcOH) as co-solvent will be demonstrated. Use of acetic acid not 
only enabled solubilization of Cipro along with povidone in water but also prevented post-
crystallization and phase separation of it in dry polymeric films after solvent (water) evaporation 
enabling fabrication of completely transparent antibiotic PVP films. Moreover, in order to overcome 
the solubility issue, same solutions were used to electrospin nanofiber (non-transparent) mats for the 
first time.  
 
2.2 Materials and Methods 
2.2.1 Materials 
Polyvinylpyrrolidone (PVP; MW = 360,000), monohydrochloride monohydrate free ciprofloxacin 
(≥98.0% HPLC; MW = 331.34), acetic acid (≥ 99.7%) were purchased from Sigma-Aldrich and used 
as received. Dimethylsulphone (DMS), heavy water (D2O) and 3-(trimethylsilyl)propionic-2,2,3,3-d4 
acid sodium salt (TSP) were obtained from Sigma Aldrich (Milan, Italy). Deionized water was obtained 
from Milli-Q Advantage A10 ultrapure water purification system.  Phosphate buffered saline (PBS) 
solution (pH 7.4) was acquired from Sigma-Aldrich and used as received.  
2.2.2 Fabrication of the films 
Cipro/polymer solutions were prepared by dissolving Cipro powder and PVP in various water/acetic 
acid solutions containing 1, 5, 10 and 30% (v/v) AcOH in 10 mL of total volume. Cipro concentration 
in the solutions was maintained at 0.1% w/v while PVP concentration was 3% (w/v). Initially, Cipro 
powder was dispersed in vials containing water/AcOH solvents, and upon complete dissolution of 
Cipro, PVP polymer was added and dissolved under mild stirring. A control solution of PVP in water at 
3% (w/v) was also prepared.  The solutions were cast on circular plastic Petri-dishes (50×50 mm) and 
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dried for 3 days under an aspirated hood under ambient conditions (16 – 20°C and 40 – 50% R.H). 
Then, the films were placed in a vacuum desiccator for 3 more days for complete removal of excess 
acetic acid. Dry transparent films had a thickness of 130 –170 µm. 
2.2.3 Preparation of the electrospun mats 
For the fabrication of the electrospun mats, identical acetic acid solutions were prepared as above. A 
more concentrated PVP polymer solution was necessary to enable electrospinning. The optimum 
concentration of PVP was found to be 25% (w/v). Cipro powder was dispersed in these solutions a 
priori such that the final blend contained 0.4% Cipro with respect to PVP polymer by weight. Mats 
were produced by means of a vertical electrospinning setup. Syringes with a stainless-steel 18-gauge 
needle were filled with the different solutions and connected to a syringe pump (NE-1000, New Era 
Pump Systems, Inc.) working at a constant flow rate of 250 µL/hr. The needle was clamped to the 
positive electrode of a high-voltage power supply generating 30.5 kV, and an aluminum disk was used 
as a collector (needle-collector distance of 24 cm). 
2.2.4 Sample Notation 
Film and fiber mat samples were classified by using two different notations: Samples labeled as P0%, 
P1%, P5%, P10% and P30% represent Cipro free PVP films or mats, obtained from solutions 
containing acetic acid with concentrations ranging from 0% to 30% (v/v). Similarly, samples labeled as 
PC1%, PC5%, PC10% and PC30% represent Cipro containing PVP films or mats with identical acetic 
acid concentration range. For film casting, PVP concentration in solution was always maintained at 3% 
(w/v) and for electrospinning PVP concentration in solution was increased and always maintained at 
25% (w/v). On a dry basis, Cipro concertation with respect to PVP in the films and mats was 3.3 wt.% 




2.2.5 Morphological analyses 
Morphology of the films and the nanofibers was analyzed by Scanning Electron Microscopy (SEM), 
using a variable pressure JOEL JSM-649LA microscope equipped with a tungsten thermionic electron 
source working in high vacuum mode, with an acceleration voltage of 5 kV. The specimens were 
coated with a 10 nm thick film of gold using a Cressington Sputter Coater – 208 HR. The diameter of 
the fibers was analyzed and determined by using ImageJ software. Approximately 150 measurements 
were taken to obtain the diameter distribution of each type of fibers. 
The transparency of all the films has been investigated by means of CARY 300 Scan UV-visible 
spectrophotometer. The absorbance values at 600 nm were followed and then divided for the thickness 
of each film. 
2.2.6 ATR FT-IR characterization 
Infrared spectra were obtained with an Attenuated Total Reflectance (ATR) accessory (MIRacle ATR, 
PIKE Technologies) coupled to a Fourier Transform Infrared (FTIR) spectrometer (Equinox 70 FT-IR, 
Bruker). All spectra were recorded in the range from 3800 to 600 cm
-1
 with a resolution of 4 cm
-1
, 
accumulating 128 scans. For the subtraction of spectra, they were previously normalized to the most 
intense band (C=O stretching mode at 1647 cm
-1
 of PVP). 
2.2.7 Nuclear magnetic resonance spectroscopy (NMR) 
Residual acetic acid quantity in the transparent films and the electrospun nanofibers was determined 
using NMR spectroscopy. Typically ca. 70 mg of sample was dissolved in 1 ml of D2O and transferred 
into 5mm tubes (Bruker). The 
1
H NMR quantitative spectra (
1
H q-NMR) were acquired on a Bruker 
AvanceIII 600 MHz spectrometer equipped with 5 mm QCI cryoprobe with z shielded pulsed-field 
gradient coil. Before each acquisition, the temperature was let equilibrate into the probe at 298.0K for 2 
min., an automatic matching and tuning were run and the homogeneity automatically adjusted. The 90° 
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pulse was optimized on each sample-tube by an automatic pulse calculation routine [157]. 16 transients 
were accumulated, at a fixed receiver gain (4), using 128 K complex data points, over a spectral width 
of 20.6 ppm with an inter-pulses delay of 30 s. An exponential line-broadening (0.1 Hz) was applied to 
FIDs before the Fourier transformation. The spectra were manually phased and automatically baseline 
corrected.  
2.2.8 Thermal analysis 
The thermal degradation behavior of the films was investigated by a standard thermogravimetric 
analysis (TGA) method using a TGA Q500 from TA Instruments. Measurements were performed on 3-
5 mg samples in an aluminum pan under inert N2 atmosphere with a flow rate of 50 mL/min in a 
temperature range from 30 to 600°C with a heating rate of 5°C/min. The weight loss and its first 
derivative were recorded simultaneously as a function of time/temperature. 
2.2.9 Water uptake 
Water adsorption measurements were carried out as follows: dry samples were weighed (~30 mg) on a 
sensitive electronic balance and then they were placed in different chambers with increasing humidity. 
The humidity conditions were: 0%, 11%, 45%, 85% and 100%. Prior to humidity chamber tests, 
samples were dried in a desiccator until no change in sample weight was measured. After conditioning 
in different humidity chambers until equilibrium conditions, each film was weighed, and the amount of 
adsorbed water was calculated based on the initial dry weight as the difference. 
2.2.10 Mechanical properties 
The mechanical properties of the films were determined by uniaxial tension tests on a dual column 
universal testing machine (Instron 3365). Films were cut in prismatic specimen with a width of 4 mm 
and an effective length of 25 mm. Displacement was applied with the rate of 3 mm/min. From the 
resulting stress-strain curves, the elastic modulus, ultimate tensile strength (UTS), elongation at yield 
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and elongation at maximum load were extracted. Measurements were performed on 5 samples per each 
sample. All the stress-strain curves were recorded at 25°C and 44% relative humidity (RH).   
2.2.11 Drug release analyses 
The release of Cipro from the transparent films and nanofiber mats was measured by using a CARY 
300 Scan UV-visible spectrophotometer. Cipro has a characteristic UV absorbance peak at 272 nm. 
Initially, a calibration curve was constructed by dissolving only Cipro. This was done by forming a 
stock solution of 10mL of water, with 10% (v/v) acetic acid and 0.1% (w/v) Cipro. The calibration 
curve was constructed by adding 75, 60, 50, 40, 30, 25, 20, 10, 5 and 2,5 µL of stock solutions in  UV-
vis cuvettes and diluting to a final volume of 3 mL. Then, the absorbance value from each cuvette was 





. For drug release measurements, films and mats were gently placed in 2.5 mL cuvettes 
containing PBS solution under constant stirring (200 rpm) and the temporal increase in absorbance at 
272 nm was monitored. After a few preliminary experiments, the optimum film weight was adjusted to 
1 mg (containing ~ 34 µg of Cipro) and the optimum electrospun mat was 6 mg (containing ~ 34 µg of 
Cipro).  
2.2.12 Antibacterial tests  
Antibacterial properties of transparent films and nanofiber mats were tested on the Gram-negative 
bacterium Escherichia coli (Thermo-Fisher Scientific), and on the Gram-positive Bacillus subtilis 
(ATCC). E. coli was cultured in LB-Broth (Sigma-Aldrich) at 37°C. B. subtilis was cultured in Difco 
Nutrient Broth (Becton Dickinson) at 30°C. 2.5 µL of each overnight bacterial culture were mixed with 
100 µL of the respective broth and gently spread onto LB-Agar plates (for E. coli, purchased from 
Sigma-Aldrich) or Difco Nutrient Agar plates (for B. subtilis, purchased from Becton Dickinson). The 
inhibition-zone assay was carried out by gently depositing samples of films or fibers (1 mg and 6 mg, 
respectively) on the center of each agar plate. The plates were incubated O/N at the appropriate 
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temperature required by each bacterial strain (37 °C or 30 °C) The next day the plates were 
photographed, and the halo of bacterial growth inhibition was calculated by ImageJ software. The 
measurements were stated as a percentage of the total area of the agar plate.  
2.2.13 In vivo full-thickness excisional skin wound healing mice model 
Male C57BL/6J mice, 8-12 weeks old (Charles River, Calco, Italy), were used for in vivo studies. They 
were maintained under a 12-hour light/dark cycle (lights on at 8:00 am) under a controlled temperature 
of (21 ± 1°C) and relative humidity of (55 ± 10%) conditions. All experiments were carried out in 
accordance with the guidelines established by the European Communities Council Directive (Directive 
2010/63/EU of 22 September 2010) and approved by the National Council on Animal Care of the 
Italian Ministry of Health. All efforts were made to minimize animal suffering and to use the minimal 
number of animals required to produce reliable results. Mice were anesthetized by intra-peritoneal 
injection of ketamine (10%), and xylazine (5%) mixture and the dorsal skin was shaved. One full-
thickness skin wound was generated in the center of the back of each animal, by a sterile 6-mm biopsy 
punch. A photo of the wound was taken immediately afterward the biopsy generation, and then covered 
with fiber-PC1%; film-PC1%, fiber-PC30% and film-PC30%. To avoid removal of the dressings by 
mice, all treated wounds were covered with Tegaderm
TM
 just before the animals woke, until the end of 
the experiment. To evaluate bio-resorption over time, the condition of each dressing has been 
photographed at different time intervals (30 seconds, 1, 3, 5, 10, 20, 30, 60, 120, 180, 240 minutes) 
after dressing application. Each acquired photograph of the dressing on the wound was analyzed by 
ImageJ software, to calculate the percentage of the bio-resorbed membrane during the time [158]. Mice 
were housed individually during the experiments, with water and food ad libitum. All animals were 





2.3 Results and Discussion 
2.3.1 Preparation and morphological analyses of films and nanofibers 
Several films were produced from water solutions containing different concentration combinations of 
Cipro, AcOH and PVP polymer as preliminary experiments (see Figure 2.2A). A proper concentration 
range among Cipro, PVP, and AcOH that can completely eliminate crystallization induced phase 
separation of Cipro within the PVP matrix during aqueous solvent evaporation. Outside of this 
concentration range, large crystal needles of Cipro in PVP films form leading to poor transparency and 
poor mechanical properties (Figure 2.2A). The optimum condition that produced completely 
transparent films with no microscopic crystal phase separation was identified as dry films containing 
3.3% by weight unmodified Cipro (see Figure 2.2B) with respect to PVP. Cipro/PVP films could be 
cast with the minimum required amount of acetic acid concentration in water corresponding to 1vol.%. 
Further verification of the absence of microcrystals of the antibiotic in the films can be found in 
Figures 2.2C and 2.2D in which SEM image of the films and optical transparency, respectively, are 
presented. A slight increase of Cipro concentration in the film to 4% by weight, while keeping the 
acetic acid concertation at 1vol.% in water, for instance, caused massive crystallization of Cipro in PVP 
as seen in Figure 2.2A. By changing the concentration of acetic acid to 2 vol.% in water, it was again 
possible to produce transparent PVP films containing 4 wt.% Cipro. Once the minimum amount of 
AcOH required was determined, identical films were cast from solutions containing 5, 10 and 30 vol.% 
AcOH in water. Antibiotic PVP films produced from solutions containing higher AcOH concertation 
were found to be softer and more flexible due to residual bound AcOH in the PVP network (after 
drying). As will be demonstrated later on, this means that AcOH is not only useful to dissolve Cipro in 





Figure 2.2 A, Crystallization/phase separation of 4 wt.% Cipro in PVP Film cast from 1 vol% acetic 
acid aqueous solution. B, Photograph of a transparent film 3.3 wt.% Cipro in PVP cast from 1 vol% 
acetic acid aqueous solution. C, SEM image of PC30% film. D, Opacity analysis of P0%, PC1%, 
PC5%, PC10%, PC30% films. 
 
From the same solutions, it was also possible to produce antibiotic-loaded fiber mats as shown in 
Figure 2.3A. Microscopic morphology of the produced mats was investigated by using SEM. Detailed 
SEM images of all the samples studied are presented in Figures 2.3B-L. As can be seen, fibers were 
produced very uniformly without beads and defects. Table 2.1 summarizes the average fiber diameter 
28 
 
of PVP and PVP-Cipro fiber mats produced by using different concentrations of AcOH. On average, 
the fiber size ranged from 250 nm to 440 nm. The largest fiber diameter was obtained by 
electrospinning sample, P0% (pure PVP with no AcOH), where the formation of some beads was also 
detected. Adding only 1vol. %  of acetic acid to the PVP water solution decreased the fiber diameter 
almost by half as seen in Table 2.1. Further increase in acetic acid concentration did not reduce the 
fiber diameter but rather comparatively increased it. Effect of acetic acid concentration on the fibers 
containing Cipro was somewhat similar, however on average, the increase in fiber diameter due to 
higher acetic acid concentration was limited to approximately 95 nm (from 315 to 410 nm) (from 1 
vol.% to 30 vol.%) compared to 140 nm (from 250 to 390 nm) in PVP (from 1 vol.% to 30 vol.%).  
Nonetheless, the presence of acetic acid ensured that the fiber sizes remained well below 1 µm, which 
is very important in obtaining high surface to volume ratio materials with porosity [96]. All of these 
properties enhance the fluid absorption [159], the dissolution rate and the release properties, especially 




Figure 2.3 A, Photograph of PC30% nanofiber mat. B-L, SEM images of PC30%, P0%, P1%, P5%, 








PVP + Cipro 
(nm) 
0  440±55 n.a 
1  250±30 315±30 
5   270±30 330±35 
10   310±30 350±30 
30   90±40 410±40 
Table 2.1 Diameter distributions of fibers in electrospun mats as a function of acetic acid 
concentration. 
 
2.3.2 Chemical characterization 
PVP and PVP-Cipro films were chemically characterized by ATR-FTIR (Figure 2.4). In Figure 2.4A 
the infrared spectra of P0%, P30%, and PC30% are shown.  Bands associated with the chemical 
structure of the polyvinylpyrrolidone and water such as O-H stretching mode at 3408 cm
-1
, asymmetric 
and symmetric CH2 stretching mode at 2955 cm
-1
 and 2883 cm
-1
, respectively, C=O stretching mode at 
1647 cm
-1
, C-N stretching mode at 1018 cm
-1
, out-of-plane C-H bending mode at 843 cm
-1
, and C-H 
rocking mode at 733 cm
-1
 were clearly observed [160]. However, some significant differences were 
detected in the spectral regions ascribed to C=O and O-H stretching vibrations. To better characterize 
these chemical differences, we subtracted the spectra of P30% and PC30% from one of the samples of 
PVP solved in pure water (P0%). The subtracted spectra, P30% - P0% and PC30% - P0%, together 
with the infrared spectra of pure ciprofloxacin and ciprofloxacin after solution in 30% acetic acid (v/v) 
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in water in the region between 1800 and 1500 cm
-1
, are shown in Figure 2.4B. For the spectrum of 
P30% - P0% the presence of acetic acid was mainly revealed by a vibration at 1719 cm
-1
 (the stretching 
mode of C=O in carboxylic acids interacting by H-bonds) and, to a lesser extent, another one at 1760 
cm
-1
 (the stretching mode of C=O in free carboxylic acids) [161]. These bands were also present in the 
spectrum of PC30% - P0% together with two additional absorptions at 1676 cm
-1
 (the stretching mode 
of C=O in carboxylic acids α,β-unsaturated) and 1624 cm
-1
 (the stretching mode of C=O in ketones) 
related to the ciprofloxacin after dissolution in 30% acetic acid (v/v) in water [162]. Interestingly, the 
infrared spectrum of pure ciprofloxacin was characterized by two bands at 1614 cm
-1
 (the stretching 
mode of C=O in ketones, note that it was shifted to lower wavenumbers) and 1587 cm
-1
 (the stretching 
mode of C=O in carboxylates α,β-unsaturated) [162], indicative of a zwitterionic structure. Hence, 
when acetic acid is added, ciprofloxacin changes its structure from zwitterion to a non-charged 
structure, as illustrated in the inset of Figure 2.4A. Finally, Figure 2.4C shows the subtracted spectra 
P30% - P0% and PC30% - P0% in the spectral region associated with the O-H stretching mode (3800-
3000 cm
-1
). In both cases, negative absorptions were observed. In PC30% - P0% this effect was higher 





Figure 2.4 A, ATR-FTIR spectra of P0%, P30% and PC30% samples. Main assignations of PVP are 
shown. The chemical structures of ciprofloxacin and PVP are drawn in the top. B, comparison in the 
spectral region of the C=O stretching mode (1800-1500 cm
-1
) of ciprofloxacin, ciprofloxacin after 
solution in acetic acid (30%, v:v) and the subtracted spectra PC30% - P0% and P30% - P0%. C, 






2.3.3 Quantification of residual acetic acid  
The acetic acid content in the samples was measured by PULCON (PUlse Length Based Concentration 
Determination) procedure [163], an external standard quantitative NMR method, that allows to measure 
the concentration of a component in a mixture, by comparing the integrated peak intensity of the signal 
of interest (e. g. the CH3 singlet of acetic acid, at 2.07 ppm) and the integrated peak intensity of a 
reference signal. As an external reference, we used a 10 mM freshly prepared solution of 
dimethylsulphone (DMS) in D2O. A deconvolution algorithm (the line fitting algorithm, MestReNova) 
was employed to separate the contribution of the acetic acid signal from the broad signals of the 
polymer [164]. The acetic acid concentration was then inferred by the ratio between the integrated 
intensity of the TSP signal (0.00 ppm), whose concentration was measured directly by using the 
PULCON method, and the integrated intensity of the acetic acid signal (at 2.07ppm). We reported the 
acetic acid content measured in each sample as a percentage in weight (Figure 2.5). Figure 2.5 
demonstrates the amount of residual acetic acid (AcOH) in the solid materials as a function of AcOH 
concertation in the starting aqueous polymer solutions. Films contain much more residual acetic acid 
then the nanofibers. The maximum residual AcOH content in the fibers is approximately 0.1% with 
respect to the polymer matrix weight originating from 30% acetic acid aqueous solution. Moreover, as 
seen in Figure 2.5, the residual AcOH content in the fibers is much less sensitive to aqueous AcOH 
concentration. On the other hand, films contain approximately 1% AcOH with respect to the polymer 
matrix weight. Films originating from 30% acetic acid aqueous solutions contain 1.4% residual AcOH 
(Figure 2.5). Nonetheless, the amount of residual AcOH is not significant and remains somewhat 





Figure 2.5 Residual content of acetic acid in the final materials as a percentage in weight. 
 
2.3.4 TGA and Water adsorption properties 
TGA and water adsorption experiments were carried out to investigate the interaction between 
polymeric chains and water, Cipro and acetic acid. The weight loss TGA curves of all the samples are 
shown in Figure 2.6A.  Derivative weight loss curves for P0%, P30%, PC30% films are presented in 
Figure 2.6B. Three major weight loss peaks were identified in all the samples. The first step, T1, 
occurred below 100°C. The second step (T2) occurred at a higher temperature in the range from 200 to 
300°C, and the third step (T3) was observed between 350 and 450°C. T1 can be attributed to the loss of 
water (environmental humidity) absorbed by the PVP matrix regardless of the acetic acid in solution. 
Main differences due to acetic acid in solution are registered in the weight loss corresponding to the T2 
region as highlighted in Figure 2.6C. P0% films (no acetic acid) displayed a T2 peak at the highest 
temperature at around 260 °C. In the presence of acetic acid T2 shifted to lower temperatures. P30%, 
for instance, displayed a T2 peak at 244 °C. In contrast, samples with ciprofloxacin exhibited T2 peaks 
between 215 and 220 °C. A higher T3 peak indicated that degradation of the polymer and Cipro 
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occurred at the same time and also indirectly indicating no phase separation and good dispersion of the 
antibiotic within the polymer matrix.  
Next, water uptake measurements of P0%, P30%, PC30% films are exemplified in Figure 2.6D. 
Interestingly, samples made with 30% v/v acetic acid in water solution were found to uptake less water 
under high humidity conditions.  The film, P0%, had the highest water uptake under high humidity.  
In view of these results, we propose the following model describing the interactions among PVP, water, 
acetic acid and ciprofloxacin molecules in the films (Figure 2.6E): In P0%, water molecules form H-
bonds with the polar groups of PVP [165]. When acetic acid is added, it partially replaces the water 
molecules due to its higher affinity towards PVP chains. This could be related to the basicity of the 
C=O group near the nitrogen atom in the main chain of PVP [166]. When Cipro is added to the acetic 
acid solution, it can also substitute water molecules due to the fact that Cipro is rich in polar and 
acid/base functional groups and each of them are latent H-bond sites [167]. This is schematically 
shown in Figure 2.5E. As more and more water molecules are substituted by AcOH or Cipro, water 
uptake is naturally expected to be reduced. Similar results and conclusions were also obtained from 




Figure 2.6 A, Thermogravimetric curve of weight loss of P0%, P30%, PC30% films B, Derivative of 
weight loss curves for pure PVP, P30% and PC30% films. C,  The values of T2 for all films prepared 
are shown. D, Water uptake as a function of relative humidity of P0%, P30%, PC30% films. E, 
Schematic representation of the chemical interaction between PVP polymer chains and water, acetic 
acid and ciprofloxacin molecules. 
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2.3.5 Mechanical properties 
PVP films cast from water solutions are highly rigid and brittle as opposed to nanofiber mats. Its 
mechanical properties are highly sensitive to ambient humidity. As shown in the previous section, 
acetic acid plasticized PVP is less prone to water uptake due to hydrogen bonding interaction between 
bound acetic acid and the polymer. Diffusion of single molecules in plasticized PVP polymer was 
shown to be more effective compared to rigid PVP, which is important for drug-loaded PVP 
applications [168]. Moreover, soft and flexible drug-loaded PVP films (see Figure 2.7B) are better 
suited for application on skin. Hence, stress-strain tests were performed to understand the effect of 
solution acetic acid concentration and Cipro loading on the mechanical properties of the PVP matrix. 
The summary of all the results is presented in Table 2.2. The stress-strain curves of P0%, P30%, 
PC1%, PC30% films are exemplified in Figure 2.7A. Pure PVP film cast from water solution, i.e., 
P0%, is a rigid plastic with an elastic modulus of about 1 GPa and cannot sustain strain rates more than 
15%. Acetic acid concentration in solution drastically changed the stress-strain characteristics of both 
pure PVP and PVP-Cipro films. Pure PVP films, produced from 30% v/v aqueous acetic acid solution, 
for instance, display elastic modulus of approximately 525 MPa (see Figure 2.7B) with more than 
150% elongation before the break (see Table 2.2). Ultimate tensile strength is also lowered as a 
function of increasing acetic acid concentration as seen in Figure 2.7C.  This indicates that soft and 
highly stretchable films with very good transparency can be made by adjusting the acetic acid 
concentration in solution.  Furthermore, the presence of Cipro in the films does not disrupt the acetic 
acid induced plasticity of the pure PVP films. The antibiotic inclusion seems to lower the elastic 
modulus further on average and somewhat enhances plasticization action on the films when aqueous 
acetic acid concentrations are above 5% v/v (see Figures 2.7B and 2.7D). For instance, elongation at 
break values of PVP-Cipro films produced from 30% v/v acetic acid aqueous solutions increased 




Figure 2.7 A, Stress–strain curves of P0%, PC1%, PC30% films. B, C, D, Young’s modulus, tensile 










Films Young’s Modulus (MPa) 
Tensile Stress at 
Max Load (MPa) 
Elongation at break (%) 
[AcOH] (%) PVP PVP Cipro PVP PVP Cipro PVP PVP Cipro 
0 1100±45 n.a. 32±2 n.a. 13±4 n.a. 
1 1050±50 1050±85 30±2 29±3 15±7 20±6 
5 970±50 950±100 27±1 18±1 27±4 64±20 
10 725±150 450±100 19±4 9±2 111±64 140±50 
30 525±100 200±125 14±4 4±2 165±67 280±100 
Table 2.2 Mechanical properties (Young’s modulus, tensile stress at maximum load and elongation at 
break) of films. Data are expressed as mean ± s.d. (n ≥ 5). 
 
2.3.6 Ciprofloxacin release studies 
Although both the films and nanofiber mats developed in this study are envisioned as skin wound 
dressings, antibiotic release and film/mat dissolution characteristics in body fluid-like liquid media are 
also of pharmaceutical importance. The release data is plotted as the ratio of antibiotic concentration in 
the release medium (PBS solution) at a given time to the initial antibiotic concentration in the film 
(C/Ctot). Effect of aqueous acetic acid concertation on the release kinetics form transparent films is seen 
in Figure 2.8A. Approximately, within the first 150 seconds (2.5 minutes) upon immersion in PBS, in 
which about 20% of the initial antibiotic concentration is released, acetic acid concentration does not 
play a substantial role. Afterward, the transparent film produced by the minimum amount of required 
acetic acid in solution (1 vol.%) releases the antibiotic slower than the others reaching 100% release in 
about 10 minutes. Other transparent films with 5 wt. % and 10 wt.% acetic acid concentration reach 
100% release condition in about half the time at 5 minutes. The film produced from aqueous solutions 
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with 30 vol.% acetic acid concentration is the fastest in releasing 100% of the antibiotic in about 4 
minutes. In the case of nanofiber mats produced with the same acetic acid concentrations, however, no 
significant effect of acetic acid concentration on the release curves is present within the experimental 
statistics, see Figure 2.8B. This could possibly be attributed to the large surface area to volume ratio 
when the composites are produced as nanofiber mats instead of films. Complete antibiotic release from 
the mats occurs within 1.5 minutes. As such, it is encouraging to see that by simply changing the 
morphology of the polymer-Cipro composites into a nanostructured one instead of a bulky film, the 
release of the full antibiotic is accelerated by about fourfold.  
Siepmann and Peppas [169] presented several detailed approaches to the use of semi-empirical 
mathematic equations for modeling drug release from hydrophilic water-soluble polymers such as 
hydroxypropyl methylcellulose. They concluded that the use of a simple empirical or semi-empirical 
model such as power laws is fully sufficient when the matrix is a hydrophilic polymer. The present 
release data from the films and the fibers were fitted with the Boltzmann equation:  
𝑦 =
𝐴1−𝐴2     
1+𝑒(𝑥−𝑥0) 𝑑𝑥⁄
+ 𝐴2 (1) 
where x0 is the center point; dx is the width; A1 and A2 initial and final y value, respectively.        
Equation (1) allows calculation of the drug release half-life (C50) corresponding to the time when half 
of the encapsulated drug is released into a perfect sink [169].  Figure 2.8C displays the half-life of both 
the transparent films and nanofiber mats produced by different acetic acid solutions in water. The 
trends in Figure 2.8C are striking in the sense that there exists a well-defined acetic acid concentration 
threshold for transparent films at around 5 wt.%. Before this threshold, increase in acetic acid 
concentration (between 0 wt.% to 5 wt.%) significantly reduces the half-life and afterward, the decline 
in the half-life is much less pronounced even if acetic acid is increased 6 fold to 30 vol.%. In contrast, 
the half-life of the nanofiber mats is an order of magnitude lower than the films, and they are much less 




Figure 2.8 A,B, Release of Ciprofloxacin from films (A) and fibers (B), respectively. C, Time needs to 
release the 50% of the total quantity, C50, of ciprofloxacin from films and fibers. 
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2.3.7 Antibacterial assays 
Pure PVP samples (P0%) placed in the plates containing E. coli did not have any effect on the bacteria 
growth (Figure 2.9A). P1% and P30% films, instead, showed an inhibition zone under and around the 
films due to the effect of bound acetic acid (Figures 2.9B and 2.9C). Inhibition zone due to P1% films 
was 0.5% of the total bacteria covered area whereas the inhibition zone increased to 30% in the case of 
P30% films (Figures 2.9B and 2.9C). PC1% and PC30% films, on the other hand, showed a broader 
zone of inhibition, compared to P1% and P30% films due to Cipro (Figures 2.9D and 2.9E). Thus, 
PC1% and PC30%, showed an increased inhibitory effect against the growth of microorganisms, due to 
the synergic effect of Cipro and acetic acid. Calculated inhibition zone percentages as a function of 
acetic acid concentration for films and nanofibers are given in Figure 2.9F. When nanofiber mats were 
tested, the synergic inhibitory effect of Cipro and acetic acid was even more pronounced than the one 
observed with the films (Figure 2.9F). Contrary to E. coli, no antibacterial effect from acetic acid alone 
was observed with the bacteria strain of B. subtilis, even at the highest concentration tested (Figures 
2.10B and 2.10C), identical to the control P0% samples (Figure 2.10A). This can be attributed to the 




Figure 2.9 A-E, Photographs show the effect of P0%, P1%, P30%, PC1%, PC30% films, respectively, 
on E. coli colonies. F, Results of the inhibition-zone assay for all samples under analysis on E. coli. 
 
Figure 2.10 A-E, Photographs show the effect of P0%, P1%, P30%, PC1%, PC30% films, 
respectively, on B. subtilis colonies. F, Results of the inhibition-zone assay for all samples under 







Thus, the behavior of B. subtilis allows us to isolate the effect of Cipro alone, as acetic acid has no 
synergistic effect. In the plates containing B. subtilis, the antibacterial effect of the Cipro containing 
films and the nanofiber mats tested was again well visible as a broad zone of bacterial growth 
inhibition (Figures 2.10D and 2.10E). Notably, the size of the growth inhibition zone was identical in 
all the Cipro samples independent of solution acetic acid concentration (Figures 2.10D, 2.10E, and 
2.10F). As such, both the transparent films and nanofiber mats functionalized with Cipro are effective 
against both Gram negative and Gram-positive bacteria. 
2.3.7 In vivo full-thickness excisional skin wound healing mice model 
To evaluate the in vivo bio-resorption and biocompatibility of antibiotic transparent films and nanofiber 
mats, they were tested in the skin full-thickness excisional mice model [171]. The biocompatibility and 
bio-resorption are key features to be monitored in the development of wound care, tissue repair and 
regenerative medicine dressings [172]. Furthermore, bio-resorption and drug release properties are 
interrelated, and resorption and rehydration characteristics should be optimum to maximize the 
therapeutic efficacy of the wound care products [173]. To evaluate the effect of acetic acid 
concentration on resorption, PC1% and PC30% samples (films and nanofibers) were tested. These 
materials were applied on fresh wounds and were monitored for a duration of 240 minutes (4 hours, 
Figure 2.11A). The application of both films and nanofibers was safe and biocompatible for the animal 
skin with no visible irritation effects. Resorption of the antibiotic films and nanofiber mats was quite 
diverse as illustrated in Figure 2.11. First of all, nanofiber mats degraded faster than transparent films. 
Even long after 240 minutes, transparent antibiotic films were not resorbed. In the case of nanofiber 
mats, for instance, at the end of 10 minutes twice as much PC1% nanofiber mat was resorbed compared 
to PC30% mat (see Figure 2.11B). At the end of one hour, however, percent resorption of both fiber 
mats were closer to each other. PC1% nanofiber mat was completely resorbed within 180 minutes after 
application on the wound, while PC30% nanofiber mat was completely resorbed within 240 minutes. 
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Moreover, as can be seen (comparing Figures 2.8 and 2.11), the rate of nanofiber mat degradation in 
vivo is much slower compared to in vitro PBS assay (2 minutes vs. 240 minutes). These preliminary 
observations on the animal models confirmed encouraging bio-resorption characteristics of the 
nanofiber mats. 
On the other hand, nanofiber mats absorbed wound exudate faster than transparent films. Exudate 
absorption can be seen as a whitish color change in transparent films due to swelling induced by 
exudate liquids (Figure 2.11A). Both PC films started to absorb wound exudates a few minutes after the 
application, although more exudate adsorption was noticed in the PC1% film compared to the PC30% 
film 180 minutes after their application on the wound (Figure 2.11A). These results indicate that 





Figure 2.11 In vivo wound healing mice model. A, Sequence of photographs displaying films and 
nanofiber mats placed fixed on mice wound. Sterile Tegaderm film cover is visible on all wounds. B, 









A non-water soluble monohydrochloride monohydrate free ciprofloxacin (Cipro) antibiotic was 
introduced into a pharmaceutical polymer, polyvinylpyrrolidone (PVP), with the help of acetic acid as 
co-solvent in water. Upon casting from aqueous solutions fully transparent antimicrobial films were 
obtained. Acetic acid prevented in situ crystallization of the antibiotic causing the unexpected 
transparency. The solutions were also electrospun into nanofiber mats (non-transparent). Residual 
PVP-bound acetic acid in dry PVP films was around 1%, and it induced unprecedented levels of 
plasticity (stretching capacity) and softness to the films. Nanofiber mats contained much less bound 
acetic acid, namely, 0.1% with respect to the weight of the polymer matrix. It also functioned as an 
antiseptic. Antibacterial properties of the films and fiber mats were tested on Escherichia coli and 
Bacillus subtilis (growth and viability). Films and nanofiber mats had promising wound resorption 
characteristics confirmed by in vivo full-thickness excisional skin wound healing mice model. 
Nanofiber mats were resorbed much faster than transparent films. Wound exudate absorption in the 
films and resorption rate of the nanofiber mats were dependent on aqueous acetic acid concentrations. 
As such, these PVP/Cipro solutions in aqueous acetic acid can be used either to produce transparent 
soft films or nanofiber mats. The fabrication process is highly suitable for designing new-generation 
potential dressings for wound management and care.  
Further characterization of these two promising antibacterial wound dressings will be shown in chapter 
4.  
 









Chapter 3 : Multifunctional 





3.1 Bilayer design as suitable strategy for multifunctional dressings 
Wound healing is a complex succession of biological events, as described in the introduction of this 
thesis. For this reason, a wound dressing has to be designed as a smart multifunctional material able to 
be active in all the phases of the recovery. One of the potential winning strategies is to make use of 
multi-layers dressings that can regulate bioactive molecule release and boost regeneration and 
remodeling of derma epithelium in a sequential manner over time [174-177]. For instance, Yannas et 
al. [178-180] were the first to propose a bilayer dressing to treat skin wounds. The design involved 
functionalized layers in which a substratum with a porous structure was made to promote cell 
migration, while a silicon-based top cover was used to avoid bacterial infections and water loss. This 
concept and the material system are now commercialized under the name Integra
®
. However, this 
construct has limitations such as poor adhesion to the wound bed, difficult removal of the artificial 
extracellular matrix after the application on the wound, and lack of active agents against infectious 
bacteria [63, 86, 87, 89, 90]. Nevertheless, Yannas et al. [178-180] bilayer structure inspired numerous 
wound dressing constructs [89, 181] and, recently, new bilayer wound gauzes have emerged. For 
instance, Reyes-Ortega et al. [182] fabricated a non-porous bilayer with a first layer of crosslinked 
gelatin-hyaluronic acid (HA) and a second one based on polyurethane derivative as a drug controlled 
release system for the delivery of two bioactive agents, proadrenomedullin N-terminal 20 peptide 
(PAMP) and bemiparin, respectively for wound healing. Likewise, Thu et al. [183, 184] demonstrated 
the application of alginate-based bilayer wound dressings as controlled release device by simply 
casting a top active layer over a bottom supportive one. Zilberman et al. [185] produced a hybrid 
bilayer comprising of a porous top layer of poly(lactic-co-glycolic acid) loaded with an antibiotic, and a 
sponge-like sublayer of collagen. Similarly, Priya et al. [34] fabricated a porous bilayer based on 
Polyvinylpyrrolidone-iodine complex (PVP-I) and gelatin. Despite these recent advances, developing 
cost-effective multi-functional and transparent wound care dressings that feature good interactions with 
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the exudate, and conformal adhesion to the wound, while promoting healing and resisting bacterial 
biofilm formation and infection, is still an appealing and challenging task [132, 186, 187]. Moreover, 
achieving such constructs using energy efficient processes and ecofriendly materials and solvents (i.e. 
water) would constitute an important benefit.  
Herein, I present a multi-functional bilayer wound dressing construct comprising polyvinylpyrrolidone 
(PVP) and hyaluronic acid (HA) as transparent matrices embedding a cutaneous antiseptic and an 
antibiotic, respectively, by using an ecofriendly water-based approach with easy scale-up potential. The 
bilayer structure consists of a top PVP layer loaded with the cutaneous antiseptic, Neomercurocromo
®
 
(Neo), and a bottom layer composite blend of HA and PVP loaded with the antibiotic Ciprofloxacin 
(Cipro). The latter layer was designed to serve two purposes, namely infection prevention/treatment, 
and potential enhancement tissue remodeling. This bilayer system is transparent, self-adhesive, flexible 
and it is capable of releasing the cutaneous antiseptic and the antibiotic in a controlled manner over a 
period of 5 days. Antibacterial tests were performed against three different strains, Staphylococcus 
aureus (S. aureus), Escherichia coli (E. coli) and Pseudomonas aeruginosa (P. aeruginosa). 
Moreover, biocompatibility, hemocompatibility and anti-inflammatory properties of the bilayer were 
evaluated in vitro. A full-thickness excision in vivo model also revealed the construct’s ability to be 
completely resorbed by the wound, most likely via integrating into the repaired tissue. Furthermore, 
both the levels of inflammatory mediators, such as IL-1β and TNF-α, and the rate of wound closure 
after the application of the bilayer were investigated. It is also demonstrated the possibility of 
fabricating the constructs using a pilot-scale rod coating technique to address the potential scale-up not 






3.2 Materials and Methods  
3.2.1 Materials 
Polyvinylpyrrolidone (PVP; MW= 360,000), monohydrochloride monohydrate free ciprofloxacin 
(Cipro; ≥98.0% HPLC; MW= 331.34), acetic acid (AcOH; ≥99.7%), glycerol, and phosphate buffered 
saline (PBS) solution (pH 7.4) were purchased from Sigma-Aldrich (St. Louis, MO, USA). Hyaluronic 
acid sodium salt (HA; MW=350,000) was purchased from Abcr (Germany). All the purchased products 
were used as received. Deionized water was obtained from Milli-Q Advantage A10 ultrapure water 
purification system. The cutaneous antiseptic was a commercial product, Neomercurocromo
®
 (Neo), 
produced by Laboratorio Farmaceutiche Specialità Igienico Terapeutiche S.I.T. s.r.l. (Pavia, Italy). Neo 
is a liquid mixture of 2.0 g of Eosin, 0.3 g of Chloroxylenol, and 30.0 g of propylene glycol dispersed 
in purified 100 mL of water with trace amounts of ethanol and sodium EDTA. According to the Italian 
drug regulatory agency (Agenzia Italiana del Farmaco, AIFA), Neo possesses high biocompatibility, it 
can be directly applied on a wound without causing discomfort or burning sensation, and it is able to 
accelerate the wound healing process. 
In particular, the functional molecule Eosin is mildly bacteriostatic against gram-positive bacteria and 
antifungal. Moreover, it can reduce the levels of pro-inflammatory cytokines and promote injured skin 
re-epithelialization [171, 188].  Chloroxylenol is a mild disinfectant and is included in the World 
Health Organization model list of essential medicines [189]. Lastly, propylene glycol favors diffusion 
of active principles through the skin and the wound tissue. Dulbecco’s modified Eagle’s medium 
(DMEM), fetal bovine serum (FBS), L-glutamine and penicillin-streptomycin were purchased from 




) was obtained from 
Sigma Aldrich (St. Louis, MO, USA). CellTiter-Glo reagent was purchased from Promega (Madison, 
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WI, USA). Human foreskin fibroblasts (HFF-1) were purchased from American Type Culture 
Collection (ATCC®). 
3.2.2 Methods for the bilayer preparation  
The bottom layer was fabricated by dissolving HA, PVP, ciprofloxacin, and glycerol in acetic acid 
(AcOH)/water solution (1% v/v in AcOH). Glycerol was used as a plasticizer that amounts to a 
concentration of 10 wt. % with respect to total polymer dry film weight. Ciprofloxacin, 0.014% (w/v), 
was dissolved in the aqueous AcOH solution. Afterward, equal weights of PVP and HA (1:1, w/w) 
were dissolved in the same solution to reach a final concentration of 2% (w/v). The solution was cast 
into circular plastic Petri dishes with a diameter of 50 mm and dried for 3 days under an aspirated hood 
in ambient conditions (16-20 °C and 40-50% relative humidity (R.H.)). For the fabrication of the 
glycerol plasticized (10 wt. % dry basis) top PVP layer containing cutaneous antiseptic Neo, two 
methods were implemented: spin-coating (smaller samples) and a spread-rod-coating (larger samples). 
A Spin-coater (model WS-650S-6NPP/LITE/OND by Laurell Technologies Co.) and a Rod-coater 
system (model EZ coater EC-200; ChemInstruments) were used, respectively. In both cases, 10 mL of 
an aqueous solution of PVP 20% (w/v), containing glycerol (10 wt. % w.r.t. PVP) and 1 mL of Neo 
was prepared.  
For the spin-coating approach (Figure 3.1A), the first layer was immobilized on a stage via air suction, 
and 4 mL of the second layer solution were added with a syringe. The spin coater was set up to run at 
1000 rpm for 3 minutes. The obtained bilayer was dried under a hood for one day at ambient conditions 
(16-20 °C and 40-50% R.H.). In the rod-coating approach (Figure 3.1B), a rectangular sample of the 
dry bottom layer (15 × 30 cm) was laid down and fixed firmly with a snap action clip, and the rod 
position was adjusted at a distance of 100 µm from the surface of the dry film. Afterward, 5 mL of the 
aqueous top layer solution were spread in the vicinity of the rod and along the rod length; the rod was 
moved from one end of the film to the other spreading the liquid over the film. The coating was 
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allowed to dry for 24 hours. Figure 3.1C shows photographs of circular spin coated bilayer constructs 
and a larger rectangular specimen with the much larger size.  
A number of reference or control samples were also prepared in order to better interpret both the drug 
release and the antibacterial efficiency of individual layers in comparison to the full construct. More 
specifically, the samples tested were full bilayer construct (BL), the bilayer construct with no 
Ciprofloxacin (BLN), the single bottom layer (SLHC), the single bottom layer only without HA 
(SLPC), and the single bottom layer without Ciprofloxacin (SLHP). The respective solution 








Figure 3.1 A, B, Schematic representation of the spin-coating and rod-coating fabrication 
processes. C, Photographs of bilayer constructs. Larger samples are made by rod coating. 





Ingredients of starting solutions (w/v) 
PVP HA Neo Cipro AcOH Glycerol 
BL 
Top Layer 20%  - 10%  -  - 2% 
Bottom Layer 2% 2%  - 0.01% 1% 0.40% 
BLN 
Top Layer 20%  - 10%  -  - 2% 
Bottom Layer 2% 2%  -  -  - 0.40% 
SLHC Single Layer 2% 2%  - 0.01% 1% 0.40% 
SLPC Single Layer 3%  -  - 0.01% 1%  - 
SLHP Single Layer 3% 2%  -  - 1% 0.40% 
Table 3.1 Composition of the fabricated samples. All the reported values represent percentages of 
material weight in the solution volume (w/v), while for the acetic acid (AcOH) the value designates a 
volume ratio (v/v). 
 
3.2.3 Morphological Analyses 
Morphology of the bilayer films was analyzed by scanning electron microscopy (SEM), optical 
microscopy (OM), and two-photon microscopy. Samples for light microscopy were obtained by cutting 
cross-section slices with Leica UCS ultramicrotome equipped with a glass knife: 1 µm thick sections 
were mounted on a glass microscope slide using Eukitt (quick hardening mounting medium – Sigma 
Aldrich). The flat cross-section of the bilayer obtained after ultramicrotome cutting was used for SEM 
analysis, after sputter coating the surface with a thin layer of gold. SEM imaging was performed using 
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SEM JEOL-JSM 6490 operating with an acceleration voltage of 10 kV. Optical images were acquired 
by a home-made microscope equipped with a 10x-0.4 NA objective (Olympus, Inc.), coupled with 
CMOS camera (Thorlabs, model DCC1645C). Two-photon microscopy characterization was carried 
out by using a NikonA1r Multiphoton coupled to a Coherent Chameleon Ti:Sapphire laser. Emission of 
Ciprofloxacin was acquired tuning the laser wavelength at 720 nm and collecting the photons with a 
450/50 bandpass filter, while the emission of Eosin was acquired tuning the laser WL at 900 nm and 
collecting the photons with a 575/50 bandpass filter.  
3.2.4 Variable-angle ATR-FTIR analysis 
Variable-angle ATR-FTIR spectra of the samples were obtained with an ATR accessory (Veemax III, 
PIKE Technologies) coupled to a FTIR spectrometer (Equinox 70 FT-IR, Bruker). All spectra were 
recorded in the range from 3800 to 600 cm
-1
 with 4 cm
-1
 resolution, accumulating 128 scans. In a 
typical measurement, the films were gently deposited on the spot of the ATR accessory (ZnSe crystal) 
and slowly pressed. The analyzed depth, dp, of ATR-FTIR spectroscopy depends on several factors 
such as the wavelength λ, the effective angle of incidence θe, the refractive index of the ATR crystal n1, 
and the sample n2, as indicated in the following equation: 
𝑑𝑝 =
𝜆
2𝜋𝑛1√sin2 𝜃𝑒−(𝑛2 𝑛1⁄ )2
   (1) 
In our variable-angle ATR-FTIR spectrometer n1 = 2.4, n2 is assumed to be around 1.5 and θe may be 
calculated from the set angle θs, n1, and the face angle of the crystal θf: 




)   (2) 
Table 3.2 shows the different θe and the dp values at 1000 cm
-1
 for all the set angles used in this study. 
All spectra were normalized to the dp at 1000 cm
-1
 using the “ATR correction” command provided for 




θs (°) θf (°) θe (°) dp at 1000 cm
-1
 (m) 
35 45 40.85 8.75 
40 45 42.92 5.73 
45 45 45 4.37 
50 45 47.08 3.55 
55 45 49.15 2.99 
60 45 51.19 2.58 
65 45 53.19 2.26 
70 45 55.14 2.01 
75 45 57.02 1.80 
Table 3.2 Calculated effective angles and analyzed depths for the different set angles used. 
 
3.2.5 Adhesion and mechanical properties 
Peel adhesion tests were carried out on a dual column universal testing machine (Instron 3365) 
equipped with a custom setup based on ISO 8510 standard: a volunteer’s human arm was placed on the 
horizontal moving table, the sample was gently applied to either dry or wet skin, and one end was 
clamped. The upper clamp was displaced upward with the constant rate of 50 mm/min; the table was 
moved horizontally by a pulley so that the peeling angle was constant (90°). The set-up is shown in 
Figure S2A (Supporting Information). The peeling force was measured throughout the test and 
normalized over the sample width. At least three repetitions were conducted for each sample. The 
mechanical properties of the full bilayer sample were determined by uniaxial tension tests using the 
same Instron 3365 dynamometer. Films were cut in dog bone specimens with a width of 4 mm and an 
effective length of 25 mm. Displacement was applied to the rate of 10 mm/min. From the resulting 
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stress-strain curves, the elastic modulus, ultimate tensile strength (UTS), elongation at yield and 
elongation at maximum load were extracted. The measurements were performed on at least 7 samples. 
All the stress-strain curves were recorded at 25 °C and 44 % R.H.  
3.2.6 Water absorption 
The water absorption capacity of the bilayer films was obtained as follows: seven dry samples were 
weighed (~ 100 mg) on a precision electronic balance and were placed in different chambers with 
controlled, increasing humidity. The humidity conditions were: 0%, 11%, 44%, 84%, 100%. Prior to 
humidity chamber tests, samples were dried in a desiccator until no change in sample weight was 
measured. After conditioning in different humidity chambers until equilibrium conditions (24 hours), 
each film was weighed, and the amount of absorbed water was calculated based on the initial dry 
weight.    
3.2.7 Drug release studies 
The release of Ciprofloxacin and Eosin (Neo) from the bilayer samples were measured using a CARY 
300 Scan UV–visible spectrophotometer. Ciprofloxacin and Eosin (Neo) present characteristic UV 
absorbance peaks at 272 nm and 517 nm, respectively. To extrapolate the molar extinction coefficients, 




 for Ciprofloxacin 




 for Eosin (Neo). Bilayer samples were cut in round shapes with a diameter of 
1.4 mm and placed in a 24-well plate, after carefully checking the correct positioning of the top and 
bottom layers by means of FT-IR measurements (bottom layer HA/Ciprofloxacin attached to the well, 
and top layer PVP/Neo facing up). Afterward, 2.5 mL of PBS were gently added into each well. At 
each time point, 300 µL of the solution were taken out and mixed with 700 µL of fresh PBS in a 
cuvette, for the UV analysis. Fresh PBS (300 µL) was added to each well, to maintain the sinking 
conditions. The experiments were carried out in an incubator at 37 °C, under controlled humidity and 
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CO2 conditions. For each sample under analysis, triplicates were considered, and the experiment was 
repeated twice. Data were expressed as a cumulative percentage.  
3.2.8 Biocompatibility assay 
3.2.8.1 Sample preparation and extraction for in vitro assay 
Samples preparation method was modified from ISO10993-12 and an extraction ratio of 1.5 cm
2
/mL 
(surface area/volume) was used to prepare the samples. In order to standardize the treatments, we 
determined the weight of the main samples under analysis corresponding to the surface area chosen, as 
reported in Table 3.3, and a weight-to-volume ratio was utilized for the extraction process (as 
extensively described in the work of Summa et al. [190]). Extraction medium from each sample was 
prepared to adapt the procedure described in ISO10993-5 standard test. Briefly, samples were sterilized 
under a germicidal UV lamp for 30 min/side, and cut into small pieces, to reduce their dimension and 
improve the extraction process. Extraction was performed in cell culture medium for 24 h at 37 °C and 
the medium was used immediately after preparation. 
 
Table 3.3 Film characterization for in vitro studies. 
Samples Weight average* (mg) S.D. (mg) 
SLHC 35.8 5.1 
BL 38.8 6.5 
BLN 40.5 5.2 






 3.2.8.2 In vitro biocompatibility assay  
HFF-1 cells were grown in DMEM supplemented with 10% FBS, 2 mM L-glutamine, 100 IU per ml 
penicillin and 0.1 mg/mL streptomycin, in a humidified incubator at 37 °C with 5% CO2. The 
cytotoxicity assay was performed using a procedure previously described [83] with slight 
modifications. Briefly, HFF-1 cells were seeded in 96-well plates at a density of 8 x 10
3
 cells and 
cultured for 24 h. Then, the culture medium was removed, and cells were treated with extraction 
medium (control samples were treated with medium processed as the extractions). After 24 hours of 




, and the extraction medium 
was replaced with fresh one. Cell viability was determined to measure ATP levels by CellTiter-Glo 
assay, as indicated by the supplier. Cell viability was expressed as percentage survival relative to 
control cells. 
3.2.8.3 Data analysis 
One-way ANOVA was used to evaluate statistical significance, followed by Bonferroni's post hoc test. 
GraphPad Prism 5 was used for all statistical analysis (GraphPad Software Inc. San Diego, CA, USA). 
p values less than 0.05 were considered significant. 
3.2.9 Hemolysis assay 
Hemolysis assay was performed using a procedure previously described by Picone et al. [191]. Briefly, 
5 mL of venous blood collected from a healthy donor was drawn directly into K2 EDTA coated 
Vacutainer tubes to prevent coagulation. After centrifugation at 500 g for 5 min, the hematocrit and 
plasma level was marked on the tube. Then, the plasma was eliminated and replaced with 150 mM 
NaCl, and the tube was centrifuged at 500 g for 5 min. This step was repeated three times, and at the 
end, the supernatant was replaced with PBS at pH 7.4. 200L of diluted (1:50 in PBS) erythrocytes 
were layering into a 96-well plate. After that, a bilayer of different weight (2, 4, 6 mg) or 10 μL of 20% 
Triton X-100, as a positive control, were added to the erythrocytes sample. The plate was incubated at 
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37°C for 3 h and then centrifuged for 5 min at 500 g to pellet whole erythrocytes. Then, 100 L of the 
supernatant was transferred from each well into a clear, flat-bottomed 96-well plate and absorbance, 
due to free hemoglobin presence, was red at 490 nm by using a plate reader (Wallac Victor 2 1420 
Multilabel Counter (PerkinElmer, Inc. Monza, Italy). After background subtraction, the average 
absorbance of the positive control was determined. All experimental data points were normalized with 
this mean absorbance value, which represents 100% hemolysis. The treated erythrocytes and the 
control were morphologically analyzed by microscopy inspection on an Axio Scope 2 microscope 
(Zeiss). 
3.2.10 ELISA tests 
Peripheral blood mononuclear cells (PBMc) were isolated from venous blood collected by young and 
healthy donors and achieved as described by Picone et al. [192]. PBMCs were incubated with 
lipopolysaccharide (LPS) (0.1 µg mL-1)  as activators of the inflammatory response, in the presence or 
not of bilayer complete for 24 h. An enzyme-linked immunosorbent sandwich assay (ELISA) 
(Invitrogen) was performed for quantitative detection of Tumor Necrosis Factor  (TNF and 
interleukin 6 (IL-6) in cell culture supernatants. 
3.2.11 Antibacterial studies 
3.2.11.1 Bacteria strains and culture conditions 
Three reference bacterial strains (the Gram-positive Staphylococcus aureus ATCC 29213 and the 
Gram-negative Escherichia coli ATCC 25404 and Pseudomonas aeruginosa ATCC 27853) were used 
for antimicrobial studies. Bacterial strains were obtained from the American Type Culture Collection 
(ATCC
®
). All the strains were cultured in Mueller Hinton Broth (MHB) and/or Agar (MHA) at 37°C. 
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3.2.11.2 Agar disk-diffusion method 
Agar disk-diffusion assay was performed against S. aureus, E. coli, and P. aeruginosa. The protocol 
was based on the M02-A document of CLSI (Clinical and Laboratory Standards Institute) for bacteria 
testing[193].Overnight cultures were centrifuged at 4500 x g, rinsed with phosphate buffered saline 
(PBS, pH 7.4) two times and resuspended in PBS to approximately 10
9
 CFU/mL. MHA plates were 
inoculated with 10
8
 CFU (equivalent to 0.5 McFarland standard) spread onto the agar surface. Samples 
were cut in 1.4 cm diameter disks and sterilized under a germicidal UV lamp (30 min/side). Dressing 
disks were placed at the center of MHA plates and incubated overnight at 37 °C. The inhibition zone 
diameters (IZDs) surrounding the tested samples were then measured using a digital caliper. Triplicate 
determinations were made for each batch of films. Films containing no drug were used as a control in 
the study. 
3.2.11.3 Time-kill kinetics test 
Time-kill kinetics of BL, BLN, and SLHC were performed against S. aureus. Samples were cut in 1.4 
cm diameter disks and sterilized as previously described. Disks were inserted in sterile 4 mL glass 
tubes and used to perform microbial incubations. The time-kill test has been performed according to the 
M26-A guideline of CLSI[194]. This guideline describes detailed procedures and analysis of results for 
bactericidal testing. Bacteria were subcultured until exponential phase in MHB, and 1 mL inoculum of 
approximately 5×10
5
 CFU/mL was added to each sample to test. After incubation at 37°C, samples 
were taken out at 0, 1, 2, 3, 6, and 24 h. In particular, 100 µL of sample were withdrawn from each 
tube, and 10-fold dilutions in sterile saline solution (0.9% NaCl) were prepared. Bacterial growth was 




) on MHA plates. Using this 
method, 7 serial dilutions were seeded on a single plate. Colonies were counted after 15 - 24 hours of 
incubation at 37 °C, and the averaged means were then transformed and expressed as mean Log10 
CFU/mL. Results were presented in the format of a “time-kill curve” by plotting the obtained viable 
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mean Log10 counts (CFU/mL) at each investigated time point for each sample and growing control 
against time (1, 2, 3, 6, 24 h). Following the approved guideline CLIS M-26A, bactericidal activity was 
defined as a 3 Log10 reduction in CFU/mL compared to the growing control [195]. One-way analysis 
of variance (ANOVA) was performed, with statistical significance defined as p < 0.05. 
3.2.12 In vivo full-thickness excisional skin wound healing mice model 
3.2.12.1 Animals 
In-vivo experiments were carried out in accordance with the guidelines established by the European 
Communities Council Directive (Directive 2010/63/EU of 22 September 2010) and approved by the 
National Council on Animal Care of the Italian Ministry of Health. 8–12 week-old male C57BL/6J 
mice (Charles River, Calco, Italy) were used. All efforts were made to minimize animal suffering and 
to use the minimal number of animals required to produce reliable results, according to the 3Rs. They 
were maintained under a 12-hour light/dark cycle (lights on at 8:00 am) under a controlled temperature 
of (21 ± 1 °C) and relative humidity of (55 ± 10%) conditions.  
3.2.12.2 Resorption test 
Dorsal skin of mice was shaved after light anesthesia induced by intra-peritoneal injection of ketamine 
(10%) and xylazine (5%) mixture. One full-thickness skin wound was created in the center of the back 
of each animal, using a sterile 6-mm biopsy punch. The wounds were photographed and then covered 
with the bilayer complete films (n = 5 for each experimental group).  
To avoid the removal of the dressings when the animals were awoken, all treated wounds were covered 
with Tegaderm™ just before the animals woke, until the end of the experiment. Photographs were 
acquired at different time intervals (1, 3, 5, 15, 30, 60, 120, 240, 360 minutes, and 24 and 48 hours), 
after the dressing application to evaluate bio-resorption over time. Each photograph of the dressing on 
the wound was analyzed by ImageJ software, to calculate the percentage of the bio-resorbed membrane 
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during the time [158]. Mice were housed individually during the experiments, with water and food ad 
libitum.  
 
3.2.12.3 Cytokine expression measurements 
Skin samples from naive, sham, and bilayer treated animals were collected 2 days post wound 
induction and snap-frozen in liquid nitrogen (n = 5 mice in each experimental group). Cytokines (IL-1β 
and TNF-α) expression were measured using ELISA quantikine kit (R & D system), according to the 
manufacturer’s instructions [171]. The cytokines concentration was normalized against the total protein 
content for a given sample, as measured using the bicinchoninic acid (BCA) assay (Thermo Scientific, 
Rockford, IL, USA). 
3.2.12.4 Wound closure investigation 
For the evaluation of the wound closure, mice were prepared as described above in the resorption 
section. Therefore, mice were anesthetized, their dorsal surface was shaved, and a full-thickness 
excisional wound was induced (diameter 6 mm). A photo of the wound was taken immediately after the 
biopsy generation (day 0). The bilayer dressing was applied, and all the treated mice were covered with 
TegadermTM to evaluate and measure wound closure photos at day 0, 3, 5, 7, 9 and 12 were collected 
and analyzed by using ImageJ software, Figure 4.10A. The wound closure was calculated as a 
percentage based on wound size relative to the control group. During the experiments, mice were 
housed individually and fed with water and food ad libitum. 
 
3.3 Results and discussion 
Selection of components and the specific structure that constitute the bilayer films are based on a 
number of reasons. The first and foremost is to demonstrate the capability to produce multifunctional 
bilayer films using eco-friendly methods with scale-up potential. Secondly, to ensure that the drug-
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loaded HA/PVP blend remains transparent. HA is a natural polysaccharide present in the human body. 
It is a component of the extracellular matrix (ECM) and synovial liquid. HA is actively involved in the 
wound healing process that promotes proliferation and migration of epithelial cells, such as 
keratinocytes, and in modulating the inflammatory response [196-202]. The synthetic polymer PVP is 
known to be a hydrogen-binding polymer, a suitable property to fabricate multi- / bi-layer systems with 
enhanced skin adhesion capability [175]. The broad-spectrum antibiotic Ciprofloxacin is also used for 
the fabrication of these materials, for more details see the previous chapter. Lastly, the cutaneous 
antiseptic Neo is a highly stable suspension that can be easily incorporated in various aqueous polymer 
solutions [171]. The reason for using 1 % acetic acid solution during the preparation of the bottom 
layer is to prevent re-crystallization of Ciprofloxacin during drying of the films to ensure transparency 
[203].   
3.3.1 Morphological attributes 
To investigate whether the two drugs remained separated and confined within their respective layers, 
measurements with single and two-photon optical microscopes were conducted. Figure 3.2A 
demonstrates the overlay of the two-photon microscopy images pertaining to the top and bottom layers 
containing Eosin (red) and Ciprofloxacin (blue), respectively. As can be seen, the top layer is about 60 
microns thick and the bottom layer is thicker, being close to 200 microns. The existence of an 
interfacial purple zone of about 10 micron thickness indicates that a limited infusion of Neo into the 
HA-PVP composite layer occurs during the coating process. This is attributed to the partial swelling of 
the bottom layer during the application and drying phase of the of the PVP-Neo coating. 
Confirmation of this observation is given by the optical microscope images of Figure 3.2B (rod 
coating) and 3.2C (spin coating). A light pink interfacial zone is also visible in both optical images. 
Further inspection of the cross section of both spin and rod coated films is conducted with SEM as 
shown in Figures 3.2D and 3.2E. The thickness of the bottom HA/Ciprofloxacin stratum was indeed 
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200 ± 20 µm, while the top PVP/Neo layer was measured to be 60 ± 20 µm thick by utilizing several 
different samples. This indicates that no significant thickness changes occur once the fabrication 
process is changed and both top and bottom layer thickness can be reproduced at different sizes 
regardless of the fabrication approach. Note that the arrows in Figure 3.2E indicate edge defects due to 
the ultramicrotome cutting during sample preparation.  
 
Figure 3.2 A, Two-photon microscope image of the bilayer fabricated by spin-coating. B, C, Optical 
microscope images of the materials obtained by rod and spin coating, respectively. D, E, SEM 
micrographs depicting the cross-section morphology of bilayer films fabricated by rod and spin 
coating, respectively. The insets show some deformations and edge effects during sample cross-section 
preparation but the samples are preserved well. 
 
3.3.2 Chemical characterization and adhesive properties  
The chemical composition of the top and bottom layers was analyzed by ATR-FTIR (Figure 3.3). 
Figure 3.3A displays the infrared spectra of both layers. Main bands of the top layer are associated with 
the functional groups present in the PVP polymer (O-H stretching mode at 3326 cm
-1
, asymmetric and 
symmetric CH2 stretching mode at 2955 cm
-1
 and 2883 cm
-1





, C-N stretching mode at 1018 cm
-1
, out-of-plane C-H bending mode at 843 cm
-1
, and C-H 
rocking mode at 731 cm
-1
) [160]. Peaks related to Neo are not distinguishable since most of its peaks 
coincide with other peaks from the polymers but also because its concentration is much lower 
compared to the polymer matrix [204]. On the other hand, the bottom layer was mainly characterized 
by the presence of both PVP and HA polymer bonding signals such as N-H stretching mode/Fermi 




 stretching mode at 1606 cm
-1
, amide II at 1558 cm
-1
, asymmetric C-O-
C stretching mode/glycosidic bond at 1150 cm
-1
, and C-OH stretching mode at 1035 cm
-1
 bands[205]. 
Additionally, both layers were analyzed at different depths from the surface. For the top layer, the main 
differences were an enlargement and shifted to lower wavenumbers of the C=O stretching mode of the 
PVP polymer (Figure 3.3B). For instance, at 1.80 μm depth the full width at half maximum (FWHM) 
and wavenumber values of this band were 49.8 and 1657 cm
-1
, respectively, and at 8.75 μm depth 
94.2 and 1645 cm
-1
, respectively. Such differences are indicative of changes in the molecular 
interactions of C=O functional groups [162]. Most likely, there is increasing interaction between the 
PVP matrix and the Neo molecules, suggesting that an increasing gradient of drug concertation could 
occur towards the interface of the two layers. On the other hand, the analysis at different depths of the 
bottom layer showed significant differences related to the relative proportion of both polymers (i.e., 
PVP/HA as the ratio between the intensities of the C=O stretching mode of PVP and C-OH stretching 
mode of HA) and a shift observed for the C-OH stretching mode of the hyaluronic acid (Figure 3.3C). 
The PVP/HA ratio exponentially decreased from a value of 2.8 at 1.80 μm depth to 1.3 at 8.75 μm 
depth, indicating that the relative HA concentration increases with the depth. Moreover, the 
wavenumber of the C-OH stretching mode attributed to the hyaluronic acid shifted by 36 cm
-1
 to lower 
wavenumbers from 1047 cm
-1
 at 1.80 μm depth to 1011 cm
-1
 at 8.75 μm. The position of this band 
depends on the hydrogen bonding network of polysaccharide OH groups [205]. Hence, this shift can be 
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related to the perturbation of the hydrogen bonding network due to PVP that also indicates the 




Figure 3.3 A, ATR-FTIR spectra of the bottom (wound contact) and top layers. Main peak assignments 
due to PVP (black) and HA (red) are shown, and their chemical structures are indicated. B, 
Enlargement (black squares) and shift (red circles) of the C=O stretching mode for the PVP/Neo layer 
with the depth of analysis. The inset shows a comparison of the C=O stretching mode (1750-1525 cm
-1
) 
of PVP/Neo layer at different depths: 1.80 μm (black line) and 8.75 μm (red line). C, PVP/HA ratio 
(black squares) and shift (red circles) of the C-OH stretching mode for the HA/Cipro layer with the 




Adhesion to human skin of the bilayer films was measured with a peel test and compared to a 
commercial medical plaster patch with an acrylic adhesive. Photograph of the set-up for the adhesion 
test, described in the methods section, is reported in Figures 3.4A. Typical peel force versus 
displacement profiles are shown in Figure 3.4B. As seen in the figure, the adhesion force profile of the 
commercial patch displays a kind of tacky/non-tacky/tacky profile such that an average adhesion force 
of 30 N/m is needed in order to peel this section (adhesive containing section) away from the skin until 
the medicated section is reached. Here, the peel force falls to practically zero. Afterward, the rest of the 
adhesive containing patch is removed with an average force of 40 N/m. Our films, however, 
demonstrate an almost constant peel force profile as shown in Figure 3.4B. The whole film can be 
removed from the skin when an average peel force of 15 N/m is applied. Although not shown, from 
each adhesion profile curve, the peak adhesion strength and the average adhesion strength can be 
estimated [206]. Doing so, even though the adhesion strength values of the self-adhering bilayer films 
(peak 31.13±12.44 N/m, average 14.61±5.94) are about half the ones of the commercial dressing that 
had been modified with an acrylic adhesive (peak 58.55±7.68 N/m, average 39.96±13.55 N/m), they 
are of the same order of magnitude.  
It should be noted that the above reported adhesion values are for moist skin and if very dry skin is 
used, the adhesion strength of the full bilayer film reduces to 2 N/m without the application of an 
adhesive. Literature data on similar 90
o
 peel tests performed with other adhesive patches on the skin, 
such as 3M Durapore® [206] and silicone-based transdermal matrix [207], showed values of adhesive 
strength between 20 and 120 N/m. Instead, hydrophilic polymer-based wound patches tested on skin 
models were shown to have an adhesive strength between 1 and 3 N/m [208, 209]. Therefore, the full 
bilayer films demonstrate satisfactory self-adhesion performance for both dry and moist human skin 
that might be associated with different levels of wound hydration/exudate. Figure 3.4C shows a 
photograph of the peel-tests conducted on a human arm for large bilayer film produced by the rod 
70 
 
coating method. Stress-strain mechanical test results of the bilayer films are shown in Figure 3.4D. The 
full bilayer is a ductile composite with an elastic modulus of 3.7 MPa, an elongation at maximum load 
of > 60%, and a tensile strength of 3.6 MPa, see the insert in Figure 3.4D. The elastic modulus is higher 
than that of human skin[210] but lower than most systems developed as wound dressings [211, 212]. 
 
Figure 3.4 A, Photograph of the instrument used for the peel adhesion tests. B, Peel adhesion 
measurements (on a human arm) for the commercial patch adhesion (black line), and the full BL film 





 peel test; the arrows indicate the displacement direction. D, Typical stress-strain curve of a full 
bilayer sample. In the insert, data of Young’s modulus, tensile strength and elongation are reported.   
 
The relatively low stiffness is expected to reduce the elastic mismatch and, therefore, improve the 
comfort of the dressing. The large elongation at fracture eliminates the risk of fracture of the dressing 
during normal body movements. Water uptake measurements revealed how the bilayer was able to 
absorb 40% of its weight of water at the highest level of humidity (100%). This value is in accordance 
with the water absorption values, between 10% and 50%, reported in the literature for several PVP and 
HA-based wound dressing [203, 213-215]. 
3.3.3 Study of drug release of Eosin and Ciprofloxacin 
Drug release measurement results from the full bilayer constructs and the reference/control samples, 
shown in Table 3.1, are reported next. In vitro drug release measurements were collected from the 
following samples: release of Ciprofloxacin and Eosin from BL (full bilayer), release of eosin from 
BLN (bilayer with no Ciprofloxacin), release of Ciprofloxacin from SLHC (bottom layer only), and 
release of Ciprofloxacin from SLPC (bottom layer only with no HA). Figure 3.5 shows the cumulative 
release outcomes of the various systems analyzed over a period of 5 days. Eosin appears to have a 
burst-like release profile from the PVP matrix, reaching 100% of release within the first 24 hours, 
regardless of the presence of Ciprofloxacin in the bilayer constructs (see Figure 3.5A top panel). 
Inspection of Figure 3.5B (top panel) that shows the release during the first 6 hours indicates that even 
though a burst-like release occurs within the first 6 hours, the rate of Neo release from both BL and 
BLN films slows down after the first hour reaching 97% release at the end. The absence of HA (SLPC) 
also causes a similar burst-like Ciprofloxacin release from PVP matrix. Similar to Neo, Ciprofloxacin 
release from SLPC is faster within the first hour as shown in Figure 3.5B (bottom panel), and at the end 
of 1-hour and 6-hours periods, more Ciprofloxacin is released to the medium compared to Neo. Once 
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HA is introduced to the bottom layer or as it is present in the full bilayer (SLHC or BL), the release of 
the antibiotic slows down significantly spanning a 5-day period as shown in Figures 3.5A and 3.5B. 
Note that when the films are soaked in the release media, drug release rates from each layer (top or 
bottom) can be affected by the presence of the other.  
It is acknowledged that in a more realistic application such as the release of the antiseptic from the top 
layer directly into a moist wound, no interference occurs due to the presence of the bottom layer. 
However, since the insertion of such drug loaded films in model release media is a well-accepted 
procedure, it is important to acknowledge such potential interferences if any. For instance, in the case 
of BL, additional thickness due to PVP top layer appears to slow down the antibiotic release, and this 
effect is more significant after the first 24 hours or so when one compares release curves in Figures 
3.5A and 3.5B. From the single layer construct of SLHC, almost all the antibiotic is released after 
about 48 hours whereas an additional 3 days are needed to discharge the entire antibiotic from the full 
bilayer construct. This is somewhat surprising if one considers that the release of both drugs from a 
single PVP film is fast and completed after 6 hours.  
Although further work and evidence may be needed, we argue that the delay in release from BL can be 
attributed to the interface between the top and bottom layer that might have additional interactions (i.e. 
hydrogen bonding) between the HA of the bottom layer and the PVP of the top layer. This can slow 
down erosive polymer loss of film dissolution, instead favoring diffusion based mechanism. Taken 
together, our results helped us define a schematic representation of the hypothetical release mechanism 
of Ciprofloxacin and Eosin from our bilayer constructs as depicted in Figure 3.5C. Note, however, that 
the herein proposed model considers the bilayer constructs placed onto a moist surface (such as a 
wound), with the PVP/HA layer not directly in contact with the moist zone. Initially, the Eosin in 
contact with the PBS is quickly released (24 hours if the zone is 100% humid) as the highly hydrophilic 
PVP matrix undergoes fast degradation or resorption. In the bottom layer, the Ciprofloxacin 
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incorporated within the PVP/HA matrix begins to diffuse outside, as a result of the PVP dissolution. 
Afterward, HA undergoes swelling and slower dissolution rate, hence regulating antibiotic release in a 
sustained manner. This model, of course, does not hold exactly if the film is fully immersed in a release 
medium since both layers contact the medium at once.  
 
Figure 3.5 A, Release profiles of Eosin (top panels) and Ciprofloxacin (bottom panels) over a period of 
24 and 120 hours, respectively. B, Release results of Eosin (top panels) and Ciprofloxacin (bottom 
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panels) for the first 6 hours. C, Schematic representation of the hypothetical drug release mechanism 
from the bilayer construct placed on a moist medium such as a wound. Potential establishment of 
hydrogen bonds within the top layer and at the interface between the top and bottom layers are shown 
as dashed lines 
3.3.4 In vitro biocompatibility assay on HFF-1 cells 
The biocompatibility of SLHC, BL, and BLN samples was assessed on HFF-1 cells. After 24 hours of 
exposure, no cytotoxic effects of the tested samples extracts were detected, as shown in Figure 4.6. No 
statistically significant differences (p > 0.05) were observed in cell survival in comparison to the 
control (given as 100%). According to ISO10993-5 guidelines, as the cell viability of the sample 
extracts were higher than 70% of the control group, all materials were considered biocompatible.  
 
Figure 3.6 Viability of HFF-1 cells after 24 hours of exposure to the samples extraction media. 
Survival values are normalized with respect to the control (set to 100%). Average percentage values ± 
S.D. of three independent experiments, each performed in three technical replicates, are shown.   
 
3.3.5 Hemocompatibility assay  
Hemocompatibility is a necessary skill for considering biosafety a material.  Blood was incubated with 
bilayer of different weights (4 and 6 mg)  for 3 hours, and the hemolysis ratio was analyzed by  
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measuring the amount of free plasma hemoglobin (Hb). As shown in Figure 3.7A, the hemolysis 
percentage induced by the presence of the bilayer in the blood sample was comparable to the untreated 
control, whereas whole hemolysis was observable in the Triton-X control sample. The result was 
confirmed by the erythrocytes microscopic observation (Figure 3.7B).   
 
Figure 3.7 A, Histogram relative to the absorbance of released Hb after treatment with 4 and 6 mg of 
bilayer films.  The values are expressed as % respect to the positive control (TritonX). B, Optical 
images of erythrocytes after the treatment with Triton X, medium, 4 mg and 6 mg of Bilayer, 
respectively. 
 
3.3.6 In vitro anti-inflammatory properties  
The inflammatory response was measured both by IL-6 and TNF production, two anti-inflammation 
mediators. PBMCs were stimulated with LPS in the presence or not of the bilayer-drug, and the images 
are shown in Figure 3.8A. In particular, LPS activation caused the formation of cell clusters an effect 
inhibited by the presence of the bilayer-drug. In the agreement, the result obtained by ELISA test 
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indicated that after LPS stimulation, PBMCs increased both IL-6  and TNF levels, whereas in 
presence of the bilayer-drug, a reduction of cytokines levels was detected (Figures 3.8B and C) 
indicating that the material has anti-inflammatory properties. 
 
Figure 3.8 A, Optical images of control samples of PBMC cells, PBMCs and LPS, and PBMC, LPS 
and bilayer, respectively. The red arrow indicates the clusters caused by the LPS presence. B, C, 
Histogram of the level of TNF-α and IL-6 quantified by ELISA and expressed in the control samples of 
PBMC cells, PBMCs and LPS, and PBMC, LPS, and bilayer. 
 
3.3.7 Antibacterial properties of the designed bilayer 
The BL bactericidal activity, against the representative Gram-positive (S. aureus) and Gram-negative 
(E. coli and P. aeruginosa) microorganisms, was assessed by disk diffusion assay. BL produced a zone 
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of inhibition of 30.6 (± 1.9) mm in S. aureus and 42.9 (± 3.2) and 39.5 (± 2.0) mm in E. coli and P. 
aeruginosa, respectively, confirming its antibacterial properties (Figures 3.9 B, D, F).  
On the contrary, the polymer dressing, used as negative control, showed no inhibition of the bacterial 
growth (Figures 3.9 A, C, E). In order to assess the pharmacodynamics of the antimicrobial agents 
present in the bilayer constructs, time-kill kinetics tests were performed against S. aureus, and results 
are shown in Figure 3.7G. The normal growth rate was represented by the growth control (CTRL) and 
SLHP dressing, which contained no antimicrobials. The kinetic profile of BLN was similar to the 
CTRL, while SLHC and BL displayed bactericidal activity, showing a ≥ 3 log10 reduction in viable 
cell count compared to the CTRL inoculum starting from 3 hour exposure. Interestingly, after 6 hour of 
treatment, BL induced significantly higher cell death compared to SLHC. This could be correlated to 
the drug release profile previously presented (Figure 3.5). Since at 6 hours a release of 75% Eosin and 
39% Ciprofloxacin was observed, the simultaneous availability of such antimicrobials amount might 
account for the more effective bacterial killing (0.83 log10). 
 
Figure 3.9 In vitro evaluation of antimicrobial activity. Agar disk diffusion method: BL was tested 
against S. aureus (B), E. coli (D) and P. aeruginosa (F). SLHP was used as negative control in both 
microorganisms (A, C, E, respectively). Time-kill kinetics is showing Log reduction against S. aureus 
(G). Data are the mean from two independent time-kill experiments. (p < 0.0001 vs SLHC). 
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3.3.8 In vivo resorption, anti-inflammatory response and wound closure of bilayer  
The in vivo bio-resorption and biocompatibility of bilayer films were evaluated in a full-thickness 
excisional wound healing mice model [171]. The material was applied to fresh wounds and monitored 
for 48 hours (Figure 3.10A). After the patch application, no visible negative effects (e.g. no color 
change or wound erosion) were noticed. The full bilayer construct showed an initial slow, regular 
tendency in exudate absorption and film degradation. After 2 hours, the patches started to absorb a high 
quantity of exudate and were swollen. The swelling process led to a more intense and visible release of 
eosin, which continued for the following 6 hours. In the first 24 hours, more than 50% of the starting 
material was reabsorbed (Figure 3.10B). More importantly, the films appeared to have a regular and 
reproducible behavior in all 5 mice used for the experiment. It can be concluded that the developed 








Figure 3.10 In vivo wound healing mice model. (A) The sequence of representative photographs 
displaying the wound treated with the bilayer film. (B) Profiles of the estimated resorbed membrane 
percentage as a function of time. 
 
Cutaneous levels of TNF-α and IL-1β were analyzed after 48 h from wound induction and, as expected, 
naive animals expressed a low level of both cytokines, indicating that no inflammation was present. On 
the contrary, a significant increase of TNF-α and IL-1β was observed in wounded/sham animals. 
Instead, in the mice treated with the bilayer dressing a reduction of 70% for TNF-α and 74% for IL-1β  
respect to the wounded/sham levels was observed, Figures 3.11A and B. These results highlighted and 





Figure 3.11 In vivo evaluation of TNF-α (A) and IL-1β (B) after 48 hours from wound induction. **p 
< 0.01 vs to the wound untreated group; *** p < 0.001 vs to the wound untreated group. 
 
Finally, the capacity of the bilayer construct to accelerate the healing process was investigated in a full-
thickness excisional wound healing mice model, and the main results are reported in Figures 3.12A and 
B. As can be noticed in the graph, Figure 3.12B, bilayer materials were able to reduce statistically (p < 
0.05) the wound area respect to the control starting from day 5. Furthermore, the wound closure was 
obtained in only 12 days for mice treated with the bilayer, suggesting faster and more effective healing 




Figure 3.12 A, Representative photographs of the skin of wound healing mice at different time points 
(day 0, day 3, day 7, day 9, and day 12): untreated (no dressing) and bilayer dressing treated wounds 
are shown. B, Time-course (days) of wound healing in mice untreated (white bars), and treated with the 













In this chapter, facile processes to design transparent bilayer drug releasing constructs that can be 
suitable for skin wound treatment were demonstrated. Two eco-friendly waterborne fabrication 
processes, namely, rod coating for large size samples and spin coating for smaller samples depending 
on the targeted wound size were used. The top PVP stratum is able to ensure a good initial adhesion to 
the skin and fast release of the cutaneous antiseptic Neo. In the top layer, HA in tandem with PVP 
ensured a more sustained release of the antibiotic, Cipro, which could potentially help in keeping an 
aseptic wound bed during the later stages of the healing process. PVP acted as an excellent transparent 
matrix for HA. In both layers, glycerol was used as a plasticizer. Peel adhesion tests revealed self-
adhering behavior to both moist and the dry human arm skin surface. Drug release experiments 
revealed that HA controls the release of Ciprofloxacin from the PVP matrix. Bilayer resulted 
biocompatibility, hemocompatibility, and capable to reduce the level of inflammatory mediators in 
vitro. The antibacterial properties of the bilayer were demonstrated against S. aureus, E. coli, and P. 
aeruginosa. The preliminary in vivo mice full-thickness wound model experiment confirmed the 
efficient resorption of our bilayer construct, while no complications or toxic effects on the wound was 
observed. Finally, the reduction of the pro-inflammatory mediators TNF-α and IL-1β and acceleration 







Chapter 4 : Testing of PVP 
Cipro wound dressings on an 
infected-wound model based on 
ex-vivo human skin  
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4.1 Biofilms and 3D infected wound human skin model 
Infections of the post-operative and chronic wound are becoming a concern, considering the increasing 
median age of the population and age-associated immune deficiency [216]. Related associated diseases, 
like diabetes mellitus or venous insufficiency, and immobility are the major conditions leading to 
chronic wounds. Moreover, in immune suppressed patients, wounds are particularly prone to infections, 
which in turn can favor and maintain the chronic inflammatory status of the wound. It is now 
recognized that chronic wounds are often associated with microbial biofilms, i.e. organized 
communities of one or several microorganism species encased and shielded by extracellular polymeric 
substances (EPS) [217, 218]. It has been demonstrated that bacteria in the biofilm are more resistant 
than planktonic bacteria and that significantly higher concentrations of antibiotics are needed to treat 
biofilm infections [55, 56]. Thus, to prevent or treat biofilm infections it is very important to realize 
high and sustained concentrations of antimicrobials at the site of infection. This is often a significant 
limitation for new potential antimicrobial drugs and is due to unfavorable drug properties like stability, 
solubility, biodistribution. Different innovative pharmaceutical formulations, like nanoparticles, 
microneedles, nanofibers, have been developed to improve systemic as well as local drug delivery and 
targeting [61, 125, 219].  
Equally important is to define the right model to simulate and test these new pharmaceutical devices.  
In literature, there are different in vitro and in vivo models to investigate antimicrobial formulations. 
Whereas in vitro mono and multicellular set-ups are limited to their 2D structure, in vivo animal models 
offers diverse advantages including three-dimensional tissue scaffold and systemic compartment. 
Nevertheless, besides the fact that the results of animal studies are not always reproducible in humans, 
the animal number in research should be limited. As an alternative to in vivo animal models, ex vivo 
models have been proposed. Ex vivo skin has been used for years to test skin penetration of chemicals 
and drugs [220]. 
85 
 
In the last years, several groups have developed 3D infection models based on ex vivo porcine or 
human skin [130, 221-225]. Even if it is easier to obtain ex vivo animal skin than retrieve ex vivo 
human skin, animal skin has different cell biology, histology, and immunology than human skin. 
Human full-thickness skin explants represent not only 3D scaffolds where bacteria can grow up but 
also represent a complex environment with extracellular enzymatic activity, antimicrobial peptides, and 
several different cell populations including active immune cells. Thus, 3D human skin models of 
wound infections are ideal animal-free systems to investigate both antimicrobial activity and the 
interaction between bacteria and skin immune system [225].  
Wound dressings loaded with Cipro could be characterized by this kind of ex vivo infected human skin 
model. Indeed, Cipro is an interesting model compound to test not only because it is poorly water-
soluble, and it can be detected by fluorescence spectroscopy but also because it was reported to inhibit 
quorum sensing in P. aeruginosa at sub-MIC concentrations leading to inhibition of the virulence of 
these bacteria even though they cannot inhibit their growth at concentrations obtainable in vivo [226]. 
In this chapter, the drug delivery property, toxicity, and efficacy of PVP-Cipro films and nanofibers 
were further investigated by using a wound model based on human ex vivo skin.  
 
4.2 Material and Methods 
4.2.1 Preparation of ciprofloxacin-loaded PVP foils and nanofiber mats 
Transparent films and nanofibers mats were prepared as described by Contardi et al. Briefly, films 
were produced by using the solvent casting method starting from aqueous solutions of PVP 3% (w/v), 
Cipro and acetic acid 30% (v/v). In this study, three different initial quantity of Cipro 1.2, 30 and 60 
mg, were combined with the polymer and the acid in water solutions with a final volume of 30 mL. The 
solutions were cast on Petri dishes (diameter 8.75 cm) for 3 days under an aspirated hood under 
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ambient conditions (16–20 °C and 40–50% R.H.).  Then, the films were placed in a vacuum desiccator 
for 3 more days for complete removal of excess acetic acid.  
The nanofibers mats were fabricated by using a vertical electrospinning set-up. Starting solutions of 
PVP, acetic acid 30% (v/v) and Cipro with a final volume of 6.2 mL were produced. A higher 
concentration of 25% (w/v) of the polymer was used to allow the electrospinning process. Similarly to 
the films, three different concentration of Cipro (2.2, 44 and 88 mM) were taken into account. Syringes 
with a stainless-steel 18-gauge needle were stuffed with the three different solutions and connected to a 
syringe pump (NE-1000, New Era Pump Systems, Inc.) working at a constant flow rate of 500 μL/h. 
The needle was clamped to the positive electrode of a high-voltage power supply generating 25/26 kV, 
and at 24 cm of distance from an aluminum disk was used as a collector (diameter of 8.75 cm). from 
each solution only 2 mL were electrospun in order to obtain the same quantity of Cipro in a circular 
area of ~201 mm
2
 (diameter 8 mm) both for films and nanofibers.  
4.2.2 Skin samples and application of superficial wounds 
Abdominal skin was obtained after informed consent from healthy donors undergoing plastic surgery, 
see Figure 4.1 point 1. The study was conducted according to the declaration of the Helsinki guidelines 
and after approval by the Ethics Committee of the Charité – Universitätsmedizin Berlin (approval 
EA1/135/06, renewed on January 2017). Subcutaneous fat tissue was partially removed keeping a layer 
of approximately 5 mm and skin pieces (1.5 x 1.5 cm) were stretched and fixed on a Styrofoam block 
using needles (Figure 4.1 point 2-3). The surface of the ex vivo skin (free of injuries or redness) was 
cleaned with double distilled water (ddH20). The epidermis was then removed with a rotating ball-
shaped milling cutter of 6 mm (No. 28725, Proxxon, Föhren, Germany) at 16,000 rpm, which was 
mounted on a dental micro motor handpiece (Marathon N7, TPC Advanced Technology, Inc. Diamond 




4.2.3 Drug penetration kinetics 
Using a punch biopsy cutter, discs of 8 mm in diameter of foils as well as nanofiber mats were cut out 
and applied on the top of the wounds. Both foils and nanofiber mats were loaded with approximately 
250 µg of ciprofloxacin. Samples were incubated at 37°C in a humidity chamber for different time 
points, after that non-penetrated material was removed with a paper towel, and the treated wound was 
removed from the rest of the tissue by means of an 8 mm punch biopsy tool. The tissue was chopped in 
small pieces and placed in 2 mL-tubes filled with 1.5 mL of 0.1 N HCl to extract ciprofloxacin. The 
samples were gently mixed on a shaker for 24 h at room temperature. Then, samples were centrifuged 
for 2 min at 300 x g, 3 x 100 µL of supernatant were removed and placed in three wells of a 96-well 
plate. Ciprofloxacin fluorescence (excitation wavelength: 275 nm, emission wavelength: 480 nm) was 
measured with an EnSpire
®
 Multimode plate reader (Perkin Elmer, Ohio, USA). A standard curve was 
prepared by dissolving ciprofloxacin in 0.1 N HCl and preparing dilutions in the range between 0.5 and 
10 µg/mL. The amount of penetrated drug was calculated on the basis of the standard curve. Results are 
presented as the means and standard deviations of three independent experiments.  
4.2.4 Toxicity of ciprofloxacin-loaded PVP foil on ex vivo skin wounds 
PVP foils, controls and 50 µg/cm
2
 of silver nanoparticles (AgNP), as a positive control, were applied 
on the top of the wound. Samples and controls were incubated in 6-well pates for 20h in 2 mL RPMI-
1640 medium without phenol red supplemented with 10% FCS, 100 µg/ml streptomycin, and 100 
I.E./ml penicillin. After that, the old medium was replaced with fresh medium added with XTT (Roche, 
Germany). After 4h, 3 x 100 µl from each sample and control were removed, placed in a 96-well 
microplate and optical density at 450 nm and 650 nm was read with the plate reader. Absorption at 650 
nm was subtracted, and the averages of the three values were calculated. Results are presented as a 
percentage with respect to the values of control wounds where 20 µL of a 0.9 % NaCl solution was 
added. Averages and standard deviation of values from three independent experiments are reported. 
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4.2.5 Bacteria inoculation and characterization of the PAO1 wound infection 
An overnight culture of the P. aeruginosa strain PAO1 (ATCC 15692) was diluted with tryptic soy 
broth. A total volume of 5 µL (containing 1x10
7
 bacteria) of this suspension was injected with a 10 µL 
syringe (26 gauge) with tapered tip (#002000, SGE Analytical Science, Ringwood Victoria, Australia) 
from the edge of the wound into the dermis (Figure 4.1 point 5). As a control, 5 µL sterile saline (0.9% 
NaCl) was injected in an uninfected control wound. Wound samples were incubated in a humidified 
chamber at 37°C for 20 h (Figure 4.1 point 6). 8 mm biopsies were taken and fixed in a solution of 4% 
formaldehyde and 0.5% glutaraldehyde (in 50 mM HEPES) for 48 hours at room temperature. Skin 
samples were then washed in 50 mM HEPES, and dehydrated in 30, 50, 70, 90, 95, 100, and 100% 
ethanol. For light microscopy (and transmission electron microscopy, not shown) samples were 
infiltrated first with a LR White/ethanol solution (1:1, 10 min.) and then with pure LR White (2 x 15 
min). Successively, samples were transferred to polyallomer centrifuge tubes (5 x 20 mm, No.342630, 
Beckman Coulter, Inc. Brea, CA, USA), containing LR White with the accelerator (5 µL/mL 
monomer). The centrifugation tubes were capped with gelatin capsule, and sample was let polymerize 
for 1 hour on ice and then at 60°C overnight. Five hundred nanometer sections were cut at the 
ultramicrotome ((EM UC7, Leica, Wetzlar, Germany), mounted on poly-L-lysine slides and incubated 
for 10 min on a 80°C thermo-plate. Sections were stained for 4 min with Richardson's stain, then 
washed with ddH2O, and imaged in the microscope (Axiophot, Carl Zeiss Microscopy GmbH, 
Germany). For SEM, after fixation one of the sample duplicates was cut with a scalpel in order to 
reveal the skin profile. The samples were then dehydrated as described above, critical point dried, 
mounted on aluminum stubs, sputter-coated with a 12 nm layer of gold-palladium and finally examined 
with a SEM (ZEISS 1530 Gemini, Carl Zeiss Microscopy GmbH, Germany) operating at 3 kV using 
the in-lens electron detector. Images have been cropped, adjusted for optimal brightness and contrast 
using Photoshop Lightroom (Adobe Systems, San Jose, CA, USA). 
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4.2.6 Antimicrobial activity of ciprofloxacin-loaded foils and nanofiber mats 
Each tested setting was done in triplicates with a total of at least three runs. The treatments with PVP 
foils and nanofiber mats were started either 1 h or 20 h after bacterial inoculation. An 8 mm punch 
biopsy was used to collect the wound tissue including some of the surrounding intact skin (Figure 3.1 
point 7). The tissue was placed in a 1.5 mL microcentrifuge tube containing 0.2 mL saline and 
homogenized for 3 min with a sterile steel pistil at 150 rpm mounted on a digital overhead stirrer (DSL, 
VELP Scientifica Srl, Usmate, MB, Italy) (Figure 4.1 point 8). After that, samples were sonicated for 
10 min in an ultrasonic bath (BactoSonic1, Bandelin, Berlin, Germany) at 40 kHz using 200 Weff to 
detach the bacteria. 100 µL of each sample were transferred to the wells of 96 well microplates, and 
diluted in 1:10 steps (20 µL sample + 180 µL saline) by using a multichannel pipette (Figure 4.1 points 
9-10). 5 µL of each well was plated on square tryptic soy agar plates. After incubation overnight at 37 
°C, spotting areas with 5 to 50 CFU were counted (Figure 4.1 points 11-12). Mean values of the 
triplicate were calculated, and the bacteria number per wound was calculated according to the used 
dilutions. In the diagrams bacteria, counts per wound are presented as the mean and standard deviation 








4.3 Results and Discussion 
4.3.1 Preparation and characterization of foils and nanofibers 
Starting from aqueous solutions of PVP, acetic acid and Cipro at different concentrations, transparent 
films and nanofibers were fabricated by using solvent casting method and electrospinning, respectively, 
as described in Figure 3.2. The final dry transparent films had a thickness of 150-180 μm and the 
absence of crystals formation was verified by SEM and opacity analysis, see Figure 2.1C and D. 
Moreover, as recently demonstrated, PVP-based films resulted in suitable wound dressings due to their 
flexibility, adhesion and resorption properties. The obtained nanofibers did not show defects or beads, 
as can be noted in Figure 2.2, with an average diameter of 400 nm.    
 






4.3.2 Different drug penetration kinetics were measured after topical application of 
ciprofloxacin-loaded foils and nanofiber mats on ex vivo wounds 
Foils and nanofibers mats (discs of 8 mm diameter) were applied on the top of the wounds created on 
the ex vivo skin to have a topically applied drug concentration of approximately 250 µg/wound. After 
different incubation times, the drug penetrated in the wound was extracted in 0.1 N HCl and measured 
by means of a fluorescence microplate reader (Figures 4.3 A and B). Amounts ranging between 6 and 
18 µg of ciprofloxacin were detected in wound extracts. Such concentrations could be maintained for 
24h in the case of foils and between 4 and 24h for nanofibers. Similar drug penetration profiles, with an 
initial increase of drug concentration in the wound followed by a decrease due to diffusion to the 
surrounding tissue, were observed for both foils and nanofibers. Both penetration kinetics could be well 
fitted to a second-degree polynomial trend line. However, lower amounts of Cipro were detected in the 
wounds treated with the nanofibers than those treated with foils. In addition, whereas foils delivered 
very quickly high amounts of ciprofloxacin (approximately 12 µg after only 2 h), the nanofibers 
reached similar concentrations later, after 6h. Interestingly, foils could maintain for over 24h a drug 
concentration in the wound between 12 and 18 µg, reaching the maximal concentration after 16h. For 
nanofiber mats, the maximal drug amounts in the wound were found already after 6 h, were maintain 
for other 10 hours of incubation and decreased to lower concentration after 24h. In a previous study, we 
have investigated the dissolution rate of both materials in phosphate buffer and on a mice full thickness 
wound model [203]. Results showed that nanofibers dissolve very quickly, within the first two hours, 





Figure 4.3 A, B, Penetration of ciprofloxacin into wounds after topical application of 
ciprofloxacin- loaded foils and nanofibers, respectively. Wounds of approximately 5 mm in diameter 
were produced in skin explants of 1.5x1.5 cm by removing superficial skin layers using a milling 
cutter. A 8 mm disc, corresponding to a dose of approximately 250 µg ciprofloxacin, was applied on 
the top of the wound and skin samples were incubated at 37°C for 2, 4, 6, 16, and 24 hours. A biopsy of 
tissue was taken chopped into small pieces and extracted in 1 N HCl. Ciprofloxacin fluorescence in 
extracts was measured and drug concentrations were calculated using a standard curve. n=3. 
 
This means that once applied on the wound, nanofibers release almost all loaded drug within the first 
incubation hours. This might result in a high local concentration whereby precipitation or 
crystallization can occur and hinder drug penetration. On the contrary, foils dissolved over a prolonged 
time of 6-8 h and released small amounts of the drug. In this way, crystallization is avoided and the free 
drug can penetrate in the wound. The fact that foils dissolve slower may also have the advantage of 
reducing skin water loss. This has a hydrating effect and might positively influence drug penetration. 
Another important aspect that should be mentioned is that, due to the spinning process, the amount of 
polymer and drug in the nanofiber mats may vary from batch to batch and even in different areas of the 
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same mat. These means that the amount of applied drug may vary from sample to sample. To avoid this 
problem, we waited for foils and nanofiber mats before application. We found that the weight deviation 
from disc to disc varied more for nanofiber mats than for foils. However, this had only a small 
influence on the amounts of the penetrated drug.  
In summary, drug penetration experiment using the 3D wound model showed that foils can deliver high 
amounts of Cipro very quickly and maintain the reached concentration over 24 hours. Such kinetics are 
desirable especially when wound are infected by bacterial biofilms, which are usually sensible only to 
high concentrations of antibiotics. In addition, high and sustained drug concentrations are necessary for 
eradication of all bacteria and avoid inducing bacterial resistance. 
 
4.3.3 Ciprofloxacin-loaded foils and nanofiber mats are not toxic toward cells of the 
ex vivo skin model 
Next, we used the 3D wound model to test if the used materials and drug concentrations are toxic to 
skin cells once applied on the top of the wound. For these experiments, after the creation of the 
wounds, the tissue blocks were placed in RPMI 1640 medium at the air-liquid interface previous 
application of the tested material. After 20h of incubation, XTT was added, and the absorption of the 
reduced metabolite was measured after 4 hours. Many cells in skin explants were still metabolic active, 
and an evident formation of the red formazan product was observed.  
Wounds treated with isotonic sodium chloride solution served as negative control, whereas silver 
nanoparticles which can release toxic silver ions served as positive controls (Figure 4.4). PVP-foils did 
not show any toxicity. This was somehow expected to be PVP a well-tolerated, FDA approved polymer 
used as a binder in tablets, as a food additive, and also as plasma volume expander [227]. Foils 
prepared to dissolve PVP in 30% acetic acid resulted to have no effect on skin viability. The tested foils 
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contain only residual amounts of acetic acid molecules incorporated within the PVP polymers, being 
most of the solvent evaporated during the preparation process, as described in the section 2.3.2 on the 
quantification of residual acetic acid.  
Finally, also the PVP foils loaded with the three concentrations of ciprofloxacin resulted to have no 
influence on the viability of skin cells. Previous studies have shown that ciprofloxacin has toxic effects 
on fibroblasts [228] and keratinocytes [229]. 
 
Figure 4.4 Toxicity of foils towards skin tissue. The XTT assay was run with skin biopsy previously 
treated with: (1) 0.9% NaCl; (2) PVP foils prepared from solutions in ddH2O; (3) PVP foils prepared 
from solutions in 30% acetic acid; (4) PVP foils loaded with 11 µg of drug; (5) PVP foils loaded with 
250 µg of drug; (6) PVP foils loaded with 500 µg of ciprofloxacin; and (7) 50 µg of PVP-coated silver 
nanoparticels. n=3 for 1-6, n=1 for 7. 
 
Toxicity was shown to be time and concentration dependent. The ex vivo model give no information 
about the type of cells been affected by applied test substances, however, in case of a material with an 
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unspecific mechanism of toxicity, like silver ions, it is a useful set up to detect over all acute toxic 
effects. 
In recent years it has been recognized that fluoroquinolones, despite being well tolerated by a broad 
portion of patients, can have rare, very disabling side effects like tendon rupture and irreversible nerve 
damage [230]. There are several hypotheses about the mechanism of toxicity and the reason why some 
persons seem to be more prone than others to develop these side effects. One theory is that there might 
be a gene variant responsible for low quinolones metabolism. Thus, drug delivery systems able to 
deliver drug locally and maintain low systemic concentrations but effective and non-toxic local drug 
levels may prevent such toxic effects. 
4.3.4 Efficacy of ciprofloxacin-loaded foils and nanofiber mats against PAO1 
infections in the 3D wound model 
A further possibility of the 3D ex vivo skin explant model is that wounds can be inoculated with 
bacteria to simulate an infection. To measure the efficacy of foils and nanofiber mats, we used the 
PAO1 infected wound model that was recently developed and characterized in our lab [130]. The used 
PAO1 strain possesses several proteolytic enzymes, among those collagenases, and use skin 
components as nutrients. Bacteria inoculated in the wounds grown from 1x10
7
 reaching a number of 
1x10
9
 bacteria per wound after 20h of incubation [130]. P. aeruginosa can grow in both aerobic and 
anaerobic conditions. Accordingly, we found bacteria deep in the wound as well as on the wound 
surface. Most of the bacteria, however, grown on the surface, despite the fact that they were inoculated 
in deeper layers of the wound. Macroscopic, the surface of the PAO1 infected wound appeared shiny 
and yellowish (Figure 4.5A). Scanning electron microscopy images of the wound surface showed 
bacteria conglomerations typical of a biofilm: three-dimensional structures, resembling towers, made of 
microbes and extracellular materials (Figures 4.5 B, C). The microscopic pictures of stained skin 
sections revealed an approximately 10 µm-thick bacteria film on the surface of the wound. The 
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scanning electron microscopic analysis of the wound profile showed the details of the bacterial biofilm. 
PAO1 microbes, together with extracellular materials as well as digested skin connective tissue, were 
piled on each other to form compact assemblies (Figures 4.5 E, F). As also shown by Schaudinn et al. 
[130], after 20h of incubation, PAO1 had grown in the wound using connective tissue as adhesion 
surface as well as a nutrient. In addition, small agglomerates or scattered bacteria were found deep in 
the tissue (Figures 4.5 D, F). These PAO1 cells were growing slower than bacteria on the wound 
surface, probably due to less favorable conditions. Nevertheless, they represent a risk for potential 
recurrent infections after treatment is completed. For this reason, the penetration of adequate drug 
concentrations in the wound and the eradication of small bacterial colonies deep in the wound tissue is 
a crucial factor for successful therapy. Thus,  
besides the possibility to study the mechanisms of PAO1 wound infections and skin immune response, 
this animal-free model offers also a 3D set up suitable for testing new anti-biofilm treatments as well as 
strategies for targeting bacteria difficult to reach, e.g. small colonies deep into the wound or 
intracellular bacteria.  
Pseudomonas aeruginosa has already been cultured on ex vivo human skin. However, different 
protocols were used in the different studies and often the induced infection was poorly characterized. 
Schmidtchen et al. used 4 mm skin biopsies that were immersed in a medium where bacteria were 
inoculated together with the treatment substance [231, 232]. Vieira et al. used ex vivo human skin to 
test the efficacy of phage therapy but no wound was induced, and PAO1 bacteria were applied on the 
skin surface, and only superficial bacteria were collected and counted after treatment [233]. 
In another study, pig skin was used, where a wound was created by a punch biopsy and a bacterial 
suspension of S. aureus was applied on the top of the wound for 2h before treatment. Nevertheless, 
bacteria were cultured and harvested only from the surface of the wound while deeper tissue infection 




Figure 4.5 Wound infection model with PAO1. A superficial wound of approximately 5 mm in 
diameter was applied on skin explants. Bacteria (1x10
7
 per wound) were inoculated and incubated in 
the skin for 20 h. A, Microscopic appearance of a representative wound after growing of PAO1 
biofilm. B, C, SEM images of wound surface at two different magnification showing the typical 
biofilm morphology of bacterial communities. D, Wound section stained with A&E showing a bacteria 
film on the surface and d more scattered bacteria deep into the wound. E, F, SEM images of skin 
sections at different magnifications showing bacterial cell agglomeration on the surface (E) and deep in 
the wound (F). 
 
In general, most of the studies did not consider the three-dimensional aspect of the model. On the 
contrary, Phillips et al. used porcine skin to model PAO1 wound infections by injecting the bacteria in 
the tissue and measuring the efficacy of topically applied treatments by extracting all bacteria at the end 
of the experiment [223]. Even if the infection was not characterized, this set up is more adequate to 
investigate the efficacy of treatment towards superficial as well as deep bacteria. 
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In this study, a similar experimental protocol to test the efficacy of innovative wound dressing 
materials was used. Further, the 3D ex vivo infection model was exploited to correlate the antibacterial 
efficacy of the tested materials with their drug delivery properties.  
The investigate foils, and nanofiber mats were loaded with three different concentrations of 
ciprofloxacin, corresponding to final concentrations of 11, 250, and 500 µg per wound. The treatment 
was applied 1h or 20h after inoculation of the bacteria in the wound followed by further 20h of 
incubation. Samples treated 1h after bacteria inoculation served to test the drug efficacy on planktonic 
bacteria (approximately 1x10
7
), whereas samples treated 20h after PAO1 inoculation served to test the 
efficacy of foils and nanofiber mats on a high concentration of bacteria (approximately 1x10
9
) 
primarily organized into a biofilm. Macroscopically, a thick, yellow biofilm was visible on the surface 
of untreated wounds after 20h of incubation, whereas no bacterial film was visible on the treated 
samples (Figure 4.6A). When applied 1h after bacterial inoculation, both foils and nanofiber mats 
resulted efficient independently from the amount of loaded drug. The 20h biofilm infection was more 
difficult to treat. The best efficacy was measured for the PVP foils (Figure 4.6B). Foils loaded with 500 
µg ciprofloxacin achieved a complete eradication of the bacteria, and the two lower concentrations 
resulted in a 3-log reduction of bacteria concentration with respect to the untreated controls. For 
nanofiber mats, a lower antimicrobial activity was measured with a maximal 3-log reduction measured 
by the highest concentration. Control experiments were also run to measure the potential antibacterial 
activity of plain PVP foils prepared using water or 30% acetic acid. No effects on bacterial growth was 
measured for these controls.  
The most striking result is that the 500 µg PVP foils achieved the complete eradication of the biofilm 
infection. The superior efficacy of the foils compared to the nanofiber mats is probably due to the 




Figure 4.6 Antimicrobial efficacy of PVP foils and nanofiber mats with different ciprofloxacin 
payloads applied to the wound 1h or 20h after PAO-1 inoculation. Representative pictures (A) and 
CFU unit counts in tissue extracts after wound infection with PAO1 and treatment with foils (B) or 
nanofibers (C) loaded with different concentrations of ciprofloxacin (Cipro) as well as plain PVP foils 
prepared from solutions in water or 30% acetic acid (D). 
 
While with the foils high drug concentrations were obtained already 2h after topical application and 
were maintained over 24h, with nanofiber mats the highest concentration was reached 6h after 
application and was already decreased after 16h of incubation. Phillips et al. assessed the efficacy of 
several commercially available treatments in porcine ex vivo wound model and found that only time-
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release silver gel and cadexomer iodine dressings were the most effective in reducing mature biofilm 
with a reduction between 5 and 7 log of 7-log total [223]. Using an in vivo mouse model, Roy et al. 
found out that ciprofloxacin-loaded keratin-based hydrogels with a sustained drug release profile could 
reduce the amount of P. aeruginosa in the wound bed by 99.9% without interfering with key processes 
of wound healing [235]. Thus, these and our results underline the importance of drug delivery systems 
with sustained release profile for an efficient treatment of P. aeruginosa wound infections. 
4.4 Conclusions 
In this chapter, on a 3D ex vivo wound infection model was investigated the efficacy and tolerability of 
PVP-based foils and nanofiber mats. The 3D model allowed to test the antimicrobial efficacy of these 
innovative materials and correlate it to their delivery properties. The results showed that, despite 
nanofiber mats dissolved faster in vitro, foils had a better delivery profile of ciprofloxacin base in the 
wound. High concentration and sustained drug delivery were required for successful eradication of the 
PAO1 biofilm infection. 
Ciprofloxacin was used as an example of a poorly water-soluble drug. PVP-based delivery systems can 
be used to load different types of antimicrobials with different molecular weight and water-solubility. 
Thus, especially the elastic, adhesive and transparent PVP-foils represent attractive new pharmaceutical 
forms for topical drug delivery. Beside their sustained drug release properties, foils also allow for more 
precise dosing of the active. Finally yet importantly, foils hold the potential for reaching high patient 
compliance because they can be applied easily and quickly also in skin areas difficult to reach for old 
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5.1 Discovering p-coumaric acid and its biological properties  
Most commercially available medical formulations derive from natural products [236]. For instance, 
there are many drug delivery systems and therapeutic approaches based on the use of biopolymers as 
well as alternative natural bio-active agents such as essential oils [83, 237, 238] and propolis [239], 
with polyphenols as their main active components. These organic chemicals are characterized by the 
presence of phenol structural units and have notable antioxidant properties [92, 240]. Among this large 
class of compounds, hydroxycinnamic acid derivatives, also known as dietary phenolic compounds, 
such as ferulic, caffeic, and p-coumaric (4-hydroxycinnamic acid, PCA) acids have gained a growing 
interest due to their remarkable biological activity: they can reduce the inflammatory response [241, 
242], show protective effect against cancer and atherosclerosis [243-246], affect the angiogenesis 
process [247-249], and interact with the β-amyloid (i.e., the main protein involved in Alzheimer 
disease), affecting the formation of toxic protein fibrils [250, 251]. For instance, Abdel-Wahab et al. 
[252] demonstrated that PCA protects rats’ hearts against doxorubicin-induced oxidative stress, while 
Ferguson et al. [253] showed that ferulic and p-coumaric acids have a better activity in comparison to 
curcumin, another common polyphenol, protecting cultured mammalian cells against oxidative stress 
and genotoxicity. On the other hand, Luo et al. [254] described a double antibacterial action 
mechanism for PCA. Recently, several studies have demonstrated that these medically beneficial 
compounds are also suitable for the treatment of skin issues due to their strong antioxidant properties 
[83, 237]. Indeed, several types of skin damages and diseases are characterized by local and/or protract 
inflammatory and oxidant events that drastically increase the levels of interleukin and free radicals, 
causing cellular damages, slowing down the healing process, and potentially driving into the chronic 
state [255]. Ghaisas et al. [256] evaluated the administration of ferulic acid as an oral solution and in 
the form of ointment for topical delivery in an excision wound model on diabetic rats that produced the 
reduction of inflammation and the acceleration of the healing process. In addition, PCA and other 
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phenolic acids have been reported as efficient photoprotective agents for skin against dangerous solar 
ultraviolet radiation (UVB) [257-259].  
Although PCA has antioxidant properties, as previously demonstrated in cultured cells [241, 244, 260] 
and animal models [260-264], its activity on cutaneous wound healing is yet to be investigated in 
detail. In this sense, incorporation of PCA in pharmaceutical polymeric matrices, like PVP, can yield 
alternative antibiotic-free biomaterials that can be used in the treatment of infected wounds. PCA 
integrated skin dressing systems can potentially regulate the levels of free radicals and pro-
inflammatory molecules for healing skin along with other important parameters, such as antibacterial 
activity, good adhesion, exudate absorption, transparency and resorbing from the skin [60]. Recently, 
we demonstrated the possibility of using polyvinylpyrrolidone (PVP) as a biocompatible polymer 
matrix for fabrication of skin wound dressing films with a high level of transparency, adhesion to the 
skin, for controlled ciprofloxacin release [203].  
Here, we present the fabrication of new biomaterials in the form of transparent, free-standing films 
composed of different proportions of PCA and PVP blended in ethanol solutions. We demonstrate that 
both components strongly interact by H-bonds and this allows the fine-tuning of thermal, mechanical, 
and hydrodynamic properties. The incorporation of PCA into PVP not only confers antioxidant and 
antibacterial properties to the polymer but also controlled the release of model drugs due to increased 
water dissolution resistance. Furthermore, PVP/PCA 2:1 films demonstrated promising activity in 
reducing matrix metallopeptidase 9 (MMP-9) levels in a wound mice model that indicates the future 






5.2 Materials and Methods 
5.2.1 Materials 
Polyvinylpyrrolidone (MW = 1300000 Da), p-Coumaric acid (≥98.0% HPLC; MW = 164.16 g/mol), 
carminic acid (CA; MW = 492.39 g/mol), methylene blue (MB; MW = 319.85 g/mol), ethanol, and 
phosphate buffered saline (PBS) solution (pH 7.4) were purchased from Sigma-Aldrich and used 
without further purification.  
5.2.2 Preparation of the films 
PVP/PCA solutions with different molar ratios were prepared by dissolving PCA and PVP powders in 
15 mL of ethanol. The solutions were first shaken (standard lab shaker) overnight, casted onto plastic 
Petri dishes (5 cm diameter), and dried for 2 days under an aspirated hood ambient conditions (16-20°C 
and 40-50% R.H.). Films with PVP/PCA molar ratio of 10:1, 7.5:1, 5:1, 3.5:1, and 2:1 were prepared, 
Table 1. The films had an average thickness of (170 ± 30) µm. Samples with higher PCA contents were 
not prepared due to the segregation of both components and macroscopic crystallization of p-coumaric 
acid. A control film of the only PVP at 3% (w/v), labeled as PVP/PCA 1:0, was also fabricated. PCA 
powder was the sample PVP/PCA 0:1.  
To investigate the dispersion and delivery of model drugs in the PVP/PCA formulation, samples loaded 
with methylene blue (MB) and carminic acid (CA), were prepared. In particular, 10 mg of MB and 15 








Table 5.1 Sample labeling, molar ratio between PVP and PCA, molar fraction of PCA, weight 





fraction of PCA 
Weight % 
of PCA 
Weight % of MB 
respect to PVP 
Weight % of CA 
respect to PVP 
PVP/PCA 1:0 1:0 0.00 0 - - 
PVP/PCA 10:1 10:1 0.09 12.8 - - 
PVP/PCA 7.5:1 7.5:1 0.12 16.3 - - 
PVP/PCA 5:1 5:1 0.17 22.6 - - 
PVP/PCA 3.5:1 3.5:1 0.22 29.5 - - 
PVP/PCA 2:1 2:1 0.33 42.2 - - 
PVP/PCA 0:1 0:1 1.00 100 - - 
PVP/PCA 1:0+MB 1:0 0.00 0 1.0 1.6 
PVP/PCA 10:1+MB 10:1 0.09 12.8 1.0 1.6 
PVP/PCA 2:1+MB 2:1 0.33 42.2 1.0 1.6 
PVP/PCA 1:0+CA 1:0 0.00 0 1.0 1.6 
PVP/PCA 10:1+CA 10:1 0.09 12.8 1.0 1.6 
PVP/PCA 2:1+CA 2:1 0.33 42.2 1.0 1.6 
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5.2.3 Scanning Electron Microscopy (SEM) 
Morphology of the films was analyzed by Scanning Electron Microscopy (SEM), using a variable 
pressure JOEL JSM-649LA microscope equipped with a tungsten thermionic electron source working 
in high vacuum mode, with an acceleration voltage of 10 kV. The specimens were coated with a 10 nm 
thick film of gold using a Cressington Sputter Coater – 208 HR. 
5.2.4 X-ray diffraction 
X-ray diffraction (XRD) measurements were performed on a PANalytical Empyrean X-ray 
diffractometer by using a Cu Kα anode (λ = 1.5406 Å) operating at 45 kV and 40 mA. The diffraction 
patterns were collected in the range 5–70° 2θ with a 0.02° step size. 
5.2.5 ATR-FTIR spectroscopy 
Infrared spectra were obtained with an ATR accessory (MIRacle ATR, PIKE Technologies) with a 
diamond crystal coupled to a Fourier Transform Infrared (FTIR) spectrometer (Equinox 70 FT-IR, 
Bruker). All spectra were recorded in the range from 3800 to 600 cm
-1
 with a resolution of 4 cm
-1
, 
accumulating 128 scans. 
5.2.6 NMR spectroscopy 
~65 mg of samples were dissolved in DMSO-d6 (deuterated DMSO) and transferred into 5 mm 
disposable tubes. NMR experiments were acquired on a Bruker Avance III 600 MHz spectrometer, 
equipped with 5 mm QCI cryoprobe, at 303K, after an automatic 90° pulse optimization. 
1
H-NMR was 
acquired with 16 transients, over a spectral width of 20.03 ppm (offset at 4.7 ppm), at a fixed receiver 
gain (1), and using 30 s of inter pulses delay. 1D-CPMG (Carr-Purcell-Meiboom-Gill) was acquired 
with 4 transient, over a spectral width of 20.03 ppm (offset at 4.7 ppm), at a fixed receiver gain (1), by 
using an inter pulse spacing of 0.3 ms, a duty cycles of 126, and 30 s of inter pulses delay. A line 
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broadening of 0.3 Hz was applied to FIDs (Free Induction Decay) before Fourier Transform. All the 
NMR chemicals shifts were referred to the not deuterated DMSO-d6 residual peak at 2.5 ppm. 
5.2.7 Thermal characterization 
The thermal stability behavior of the films was investigated by a standard thermogravimetric analysis 
(TGA) method, using a TGA Q500 from TA Instruments. Measurements were performed with 3-5 mg 
samples in an aluminum pan under inert N2 atmosphere with a flow rate of 50 mL/min in a temperature 
range from 30 to 600°C and with a heating rate of 5°C/min. The weight loss and its first derivative 
were recorded simultaneously as a function of time/temperature. Differential Scanning Calorimetry 
(DSC) thermograms were acquired with a DSC Q20 (TA Instruments) from RT to 200 °C under 
nitrogen flow (50 mL/min) at 20 °C/min using non-hermetic aluminum pans. About 4 mg (weighted 
with +0.00001 g precision) of the sample were used. Specimens were first heated to 150 °C to release 
moisture, cooled to RT and finally ramped to 200 °C. The glass transition temperature (Tg) was 
calculated using the inflection method. 
5.2.8 Water absorption 
The water absorption capacity of the films was obtained as follows: dry samples were weighed (~100 
mg) on a sensitive electronic balance and placed in different chambers with controlled, increasing 
humidity. The humidity conditions were: 0%, 11%, 44%, 84%, 100%. After conditioning in different 
humidity chambers until equilibrium conditions (usually 24 h), each film was weighed, and the amount 
of absorbed water was calculated based on the difference between the weight of each film and its initial 
dry weight.    
5.2.9 Water contact angle 
Static water contact angle measurements were performed by using the sessile drop method with a 
DataPhysics OCAH 200 contact angle goniometer equipped with a CCD camera and image processing 
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software operating under laboratory conditions (temperature 22–25 °C and relative humidity 50–60%). 
For the characterization, droplets of 1 µL volume MilliQ water were used. Up to 10 contact angle 
measurements were carried out on each sample at random locations, and their average values and 
standard deviation were reported.  
5.2.10 ABTS free radical cation scavenging assay 
The ABTS radical cation (ABTS
·+
) was generated by the reaction between 7 mM ABTS water solution 
with 2.45 mM potassium persulfate solution in the dark at room temperature for 12-16 hours. The 
ABTS
·+
 solution was diluted with water to obtain an absorbance of 0.80 a.u. At 734 nm. After that, 5x5 
mm
2
 films were added to 3 mL of diluted ABTS
·+
 solution. The decrease in absorbance was determined 
at 734 nm with a Cary 300 Scan UV-visible spectrophotometer at different times. All the measurements 
were performed in triplicate, and the results were averaged to obtain a mean value. Radical scavenging 
activity (RSA) was expressed as the inhibition percentage of free radical of the sample and calculated 
as follows[255, 265]: 
𝑅𝑎𝑑𝑖𝑐𝑎𝑙 𝑆𝑐𝑎𝑣𝑒𝑛𝑔𝑖𝑛𝑔 𝐴𝑐𝑡𝑖𝑣𝑖𝑡𝑦 (%) =  
𝐴0 −  𝐴1
𝐴0
 𝑥 100 
where A0 is the absorbance value of the control radical cation solution, and A1 is the absorbance value 
of the sample at different times.  
5.2.11 Mechanical tests 
The mechanical properties of the PVP/PCA samples were determined by uniaxial tension tests on a 
dual column universal testing machine (Instron 3365). Films were cut in dog bone specimens (at least 
seven of them for each sample) with a width of 4 mm and an effective length of 25 mm. Displacement 
was applied at a rate of 10 mm/min. The Young’s modulus, stress at maximum load, and elongation at 
break were calculated from the stress-strain curves. All the stress-strain curves were recorded at 25 °C 
and 44 % R.H. 
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5.2.12 Drug release studies 
The release of PCA, MB, and CA from PVP-PCA films was performed by using a Cary 300 Scan UV-
visible spectrophotometer. PCA, MB, and CA present characteristic UV absorbance peaks at 334, 664, 
and 528 nm, respectively. Calibration curves were made to calculate the molar extinction coefficients 













 for CA. Samples were cut in round shapes with a diameter of 0.8 mm and placed in 24-well plates 
with 2.5 mL of PBS. For the release of PCA, at each time point (1, 5, 10 15, 20, 30 minutes and 1, 2, 3, 
4, 6, 8, 12, 24, 48, 72 hours), 100 µL of the solution were taken out and substituted with 100 µL of 
fresh medium. Similarly, in the release studies of MB and CA release, at the given times points, 500 µL 
of the solution were taken out and replaced with 500 µL of fresh PBS. All the measurements were 
carried out at room conditions (22–25 °C and 50–60% R.H.). For each sample, triplicates were used 
and the experiment was repeated twice. 
5.2.13 Antibacterial tests 
0.5 cm
2
 pieces of PVP-PCA 1:0, 10:1, 5:1, and 2:1 films were sterilized under UV at 254 nm for 30 
minutes. 50 µL of a diluted (1:10
4
) Gram-negative Escherichia  coli (E. coli) or Gram-positive 
Staphylococcus aureus (S. aureus) cultured overnight were spread on LB or blood agar plates 
respectively, and after 10 minutes the film samples were placed in the center of the plates and 
incubated at 37 °C overnight. The inhibitory effect on bacterial growth was determined by measuring 
the radius of the bacteria-free zone. 
5.2.14 Full-thickness skin wound model 
In vivo experiments were performed according to the guidelines established by the European 
Communities Council Directive (Directive 2010/63/EU of 22 September 2010) and approved by the 
National Council on Animal Care of the Italian Ministry of Health. 8–12 weeks old male C57BL/6J 
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mice (Charles River, Calco, Italy) were used. They were maintained under a 12-hour light/dark cycle 
(lights on at 8:00 am) under a controlled temperature of (21 ± 1) °C and relative humidity of (55 ± 10) 
% conditions. All efforts were made to minimize animal suffering and to use the minimal number of 
animals required to produce reliable results. The dorsal skin of mice was shaved after light anesthesia 
induced by intra-peritoneal injection of ketamine (10%) and xylazine (5%) mixture. One full-thickness 
skin wound was created in the center of the back of each animal, using a sterile 6-mm biopsy punch. 
The wounds were photographed and covered with PVP/PCA 2:1 or PVP/PCA 10:1 films (n = 5 each 
experimental group). To avoid the removal of the dressings when the animals awake, all treated 
wounds were covered with Tegaderm™ just before the animals woke, until the end of the experiment. 
To evaluate bio-resorption over time, the condition of each dressing has been photographed at different 
time intervals (1, 3, 5, 15, 30, 60, 120, 240, 360, 1440 min) after film application with a Microscope 
Leica digital camera. ImageJ software was used for the analysis of each picture to calculate the 
percentage of the bio-resorbed membrane during the time[158]. Mice were housed individually during 
the experiments, with water and food ad libitum. All animals were sacrificed at the end of the 
experiment by carbon dioxide euthanasia. 
5.2.14 MMP-9 measurement by Western blot 
Skin samples from Naïve, Sham, PVP/PCA 2:1, and PVP/PCA 10:1 groups were collected 48 h post 
wound induction and stored at -80 °C. Tissues were homogenized in lysis buffer (150 mM sodium 
chloride, 50 mM Tris·HCl, pH 8.0, 0.5% sodium deoxycholate, 0.1% SDS, and 1% Triton X-100). The 
tissue extract was cleared by centrifugation (15 min at 12000x g, 4 °C). Proteins (30 μg) were separated 
by SDS/PAGE and transferred to nitrocellulose membranes. Anti–MMP-9 (1:100; Abcam) and 
antiGAPDH (1:2000; Abcam) antibodies were used followed by incubation with, respectively, anti-
rabbit and anti-mouse IgG antibody (1:5000; Millipore). Finally, MMP9 and GAPDH were visualized 
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with a chemiluminescence kit (Bio-Rad). Images were obtained by using a LAS-4000 lumino-image 
analyzer system (Fujifilm). 
 
5.3 Results and Discussion 
5.3.1 Morphological characterization 
Figure 5.1A shows the photographs of PVP/PCA samples. As observed, all of them were transparent. 
PVP/PCA 1:0 (pure PVP) was colorless while a light orange color started to appear as the PCA content 
was increased due to the presence of the phenolic acid [266, 267]. The micro-morphology was also 
analyzed by SEM, Figure 5.1B. A flat, featureless, smooth surface was observed for all samples, with 
no presence of aggregates, segregation or PCA crystals, indicating that the polymer and the phenolic 
acid were miscible in the concentration range investigated, as confirmed in the following sections.  
5.3.2 Chemical and structural characterization 
The miscibility and crystalline structure of pure PVP, p-coumaric acid, and the corresponding blends 
were characterized by XRD in Figure 5.2A. PVP showed two broad halos centered at 10.8 and 20.8°, 
typical of the amorphous structure of the polymer [25, 268]. On the other hand, pristine PCA exhibited 
an XRD pattern with multiple narrow peaks indicative of a well-defined monoclinic crystal system 
characteristic of the acid [269]. The diffraction patterns are shown in Figure 5.2A. The absence of 
crystalline peaks from PCA fraction in the blends revealed that the acid was included in the amorphous 
structure of the polymer matrix. As such, no phase separation was determined, suggesting a high-level 
of miscibility between both components. Similar behavior has been described for solid dispersions of 
PVP with other drugs such as curcumin, piroxicam, ketoconazole, and flunarizine [24-26, 268]. To 
further investigate the interactions between PVP and PCA, ATR-FTIR spectroscopy was carried out as 




Figure 5.1 A, B, photographs and SEM top-view images, respectively, of PVP/PCA samples. 
 
Figure 5.2B shows the infrared spectra of PVP, p-coumaric acid, and PVP/PCA 2:1, 5:1, and 10:1 
samples. Main bands of PVP were associated with the chemical structure of the polymer: O-H 
stretching mode at 3403 cm
-1
, asymmetric and symmetric CH2 stretching mode at 2951 and 2868 cm
-1
, 
respectively, C=O stretching mode at 1645 cm
-1
, C-N stretching mode at 1018 cm
-1
, out-of-plane C-H 
bending mode at 845 cm
-1
, and C-H rocking mode at 735 cm
-1 
[160]. On the other hand, PCA was 
characterized by the following bands: O-H stretching mode at 3375 cm
-1
, C=O stretching mode at 1685 
cm
-1
, C=C stretching mode at 1668 cm
-1
, two in-plane C-H deformation modes at 1215 and 690 cm
-1
, 
and out-of-plane C-H bending mode at 829 cm
-1
 [270]. For the blends, most of the bands overlapped in 
the spectral region between 1800 and 600 cm
-1
. However, a new band at ~3175 cm
-1
 related to 
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hydroxyl groups interacting by strong H-bonds appeared, Figure 5.2C. The intensity of the band was 
higher, and the wavenumber lower as the PCA content increased, revealing a stronger H-bond network 
between the polymer matrix and the acid depending on the amount of p-coumaric acid. In the end, the 
formation of any kind of chemical bond between both species during the preparation of the films was 
discarded, as checked by NMR and reported in Figures 5.3 and 5.4. 
The 
1
H NMR spectrum of PVP shows signals between 1 and 4 ppm whose assignments are reported in 
Figure 5.3A. Such signals are broad and with unresolved fine structure, characteristic of polymers (with 
short T2, the transversal correlation time). On the contrary, signals between 6.26 and 7.53 ppm are 
sharp and with a recognizable multiplicity, typical of small molecules (with long T2 time) [271]. 
Assignments, in such a region, reported in Figure 5.3B, are attributed to the p-coumaric acid moiety 
(region of double bonds and aromatic 
1
H). Such signals remain substantially unaffected by applying a 
1D-CPMG [272] acquisition scheme Figure 5.4 while the broad signals belonging to the PVP moiety 
are reduced in intensity down to the baseline. We can thus exclude that the p-coumaric acid is 




Figure 5.2 A, XRD patterns of PVP/PCA samples. Several crystalline peaks are detected for PVP/PCA 
0:1, while the rest of the samples show two broad bands. Main assignations of the XRD pattern of 
PVP/PCA 0:1 are included. B, ATR-FTIR spectra of PVP/PCA 1:0, 10:1, 5:1, 2:1, and 0:1. Main 
assignments of pure PVP and p-coumaric acid are included. C, variation of the OH stretching band for 
PVP/PCA 1:0, 10:1, 5:1, 2:1, and 0:1 samples. The arrow is a visual guide that indicates the shift of the 
















H NMR and 1D-CPMG of the PVP/PCA 10:1 sample in DMSO-d6. The PVP signals are 
suppressed after the application of a 1D CPMG acquisition scheme, while the signals of PCA are only 
slightly decreased in intensity (due to their intrinsic T2 resonance decay). Analogous results were 
obtained with all the samples. 
 
5.3.3 TGA and DSC analysis 
The thermal properties of the PVP/PCA samples were evaluated by TGA and DSC, Figure 5.5. Figure 
5.5A shows the thermogravimetric analysis of PVP/PCA 0:1, 2:1, 5:1, 10:1, and 0:1 samples. For pure 
PCA an intense weight loss of ~87% at 216°C related to the thermal decomposition of the molecule 
was observed [273]. On the other hand, PVP showed two different thermal events at 64°C and 427°C 
(weight losses of ~16 and ~84%, respectively) associated with the evaporation of the retained solvent 
and the degradation of the polymer backbone, respectively [274]. The TGA for the blends displayed an 
intermediate behavior with events from both components. However, as the amount of the acid 
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increased, a shift to lower values of the maximum decomposition temperature of PCA was determined, 
inset of Figure 5.5A, suggesting good miscibility between both components [275]. 
DSC characterization of PVP/PCA samples showed a single glass transition in Figure 5.5B. No thermal 
events associated with melting or crystallization processes were observed, indicating the amorphous 
nature of films, as previously confirmed by XRD. The glass transition temperature linearly decreased 
from 183°C for pure PVP to 91°C for PVP/PCA 3.5:1, then the value slightly decreased to 89°C for 
PVP/PCA 2:1. Such depression of the glass transition temperature is typical of a plasticization of 
polymer matrixes by addition of molecules that weaken selective intermolecular interactions between 
polymer chains and increase the free volume of the system. In this case, PCA molecules by formation 
of H-bonds with PVP, as elucidated by infrared spectroscopy, can effectively separate the polymer 




Figure 5.5 A, TGA thermograms (top) and derivative thermogravimetric curves (bottom) of PVP/PCA 
0:1, 2:1, 5:1, 10:1, and 0:1 samples in the range of temperatures between 25 and 800°C. Main thermal 
events are highlighted. The inset in the bottom graph shows the temperature of maximum degradation 
of p-coumaric acid as a function of the mole fraction of PCA. B, DSC curves of PVP/PCA 0:1, 2:1, 5:1, 
10:1, and 0:1 samples in the range of temperatures between 40 and 200°C. The glass-transition 
temperatures have been highlighted with grey dashed lines. The inset shows the variation of the Tg with 
the mole fraction of PCA in the film. 
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5.3.4 Mechanical characterization 
The mechanical properties were evaluated by tensile tests, Figure 5.6. Figure 5.6A displays the typical 
stress-strain curves of the films, while the values for Young’s modulus, stress at maximum load, and 
the elongation at break are plotted as functions of the mole fraction of PCA in Figures 5.6B,C,D, 
respectively. Pure PVP presented the behavior of a rigid polymer with high Young’s modulus and 
stress at maximum load (1095 and 25 MPa, respectively) and low elongation at break (3.7%). When 
small amounts of PCA were added, (PVP/PCA 10:1 and PVP/PCA 7.5:1 samples) PCA acted as a 
reinforcement agent increasing Young’s modulus and stress at maximum load and keeping the value 
for elongation at break. From this molar ratio, samples with richer contents of the acid became ductile 
reducing their values of Young’s modulus and stress at maximum load and increasing the elongation at 
break. In particular, Young’s modulus, stress at maximum load, and elongation at break were 35 MPa, 
0.75 MPa, and 300%, respectively, for the sample with the highest PCA content (PVP/PCA 2:1). This 
change from rigid to ductile behavior is commonly associated with a lower interaction between 
polymer chains caused by the interference of external molecules. This phenomenon together with the 
depression of Tg caused by the presence of p-coumaric acid, as determined by DSC, are indicative of a 




Figure 5.6 A, stress-strain curves of PVP/PCA films. The inset shows a magnification at low strain 
values. B, C, D, variation of Young’s modulus, stress at maximum load, and elongation at break, 
respectively, with the mole fraction of PCA.   
 
5.3.5 Water uptake, water contact angle, and antioxidant capacity 
Figure 5.7A shows the water uptake of PVP/PCA samples at different values of relative humidity. Pure 
PVP presented the highest increase of weight, while the samples with PCA showed a regular decrease 
in their capacity to uptake water. This trend was also observed by plotting the values obtained at 100% 
RH, Figure 5.7B. The water uptake decreased from ~36% for PVP/PCA 1:0 to ~9.5% for PVP/PCA 
3.5:1 and, then, slightly was reduced to ~6% for PVP/PCA 2:1. Such a decrease is attributed to the 
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interaction of p-coumaric acid molecules with the polar functional groups of PVP, thus reducing the 
number of potential anchor points for water. The results of the water contact angle analysis are 
presented in Figure 5.7C. The wettability depended on the relative proportion of both components. Pure 
PVP and PVP/PCA 10:1 were hydrophilic with WCA values of 55 and 73°, respectively. For higher 
PCA contents, the samples become hydrophobic with water contact angles close to 100°. Similarly to 
water uptake, this phenomenon can be related to a lower presence of available polar groups on the 
surface due to the interaction between PVP and PCA. Finally, in Figure 5.7D, the antioxidant 
properties of the films expressed as RSA percentages are reported. As expected, all the films loaded 
with PCA showed a high antioxidant capacity, reaching 100% RSA after 1 hour, while RSA 





Figure 5.7 A, water uptake of PVP/PCA samples as a function of relative humidity. B, values of water 
uptake of PVP/PCA films at 100% of relative humidity. C, variation of water contact angles with the 
mole fraction of PCA in the films. D, radical scavenging activity of PVP/PCA samples as a function of 
time.   
 
5.3.6 Study of drug release of PCA, MB, and CA 
Drug release experiments were carried out to investigate the PCA release from the PVP-based materials 
and verify the possibility to use the PVP/PCA system for the delivery of other drugs. In Figure 5.8A, 
the main results of PCA release are displayed and expressed as cumulative percentages. PVP/PCA 10:1 
and 7.5:1 samples showed a burst-like release profile, reaching the maximum release of PCA in 2 and 3 
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hours, respectively. Instead, PVP/PCA 5:1, 3.5:1, and 2:1 films showed a slower release, with 
maximum releases at 24, 48, and 72 hours respectively. The release during the first 24 hours is shown 
in Figure 5.8B. At this time, the PCA release from PVP/PCA 5:1, 3.5:1, 2:1 samples was 97%, 83%, 
and 43%, respectively. As observed, the release was slower as the PCA content was higher. 
Figures 5.8C,D shows the release profile of MB and CA, respectively, from PVP/PCA 1:0, 10:1, and 
2:1 samples. Pure PVP showed the fastest releases for both drugs, by reaching 99% and 91% of the 
release for MB and CA, respectively, in 30 minutes. Likewise, the release of the two model drugs from 
the PVP/PCA 10:1 system was completed in ~2 hours. On the other hand, the release of the model 
drugs from PVP/PCA 2:1 matrix took much longer. The samples PVP/PCA 2:1 + MB released  93% of 
the blue dye in 48 hours. Similar behavior was observed for the sample   PVP/PCA 2:1 + CA where 
89% of the red dye was released in 48 hours. The low releases found in PCA-rich samples can be 
caused by a high chemical affinity between MB, CA, and PCA. All these molecules have aromatic 
rings and polar groups that allow the interaction between them by different secondary bonds such as -
 or dipole-dipole interactions and H-bonds [276].  
Kinetics data regarding PCA release showed how these release profile fitted with first order kinetics. 
Moreover, a reduction of the rate constants in the samples with a higher concentration of PCA was 
observed, see Figure 5.9. Indeed, from the drug release data shown in Figures 5.8A and B the apparent 
rate constants were calculated, Figure 5.9. The increase of cumulative percentages was empirically best 
fitted to a ln(1-P) = -kt first-order kinetic law, where P is the fraction of PCA released at time t and k is 
the apparent rate constant. As an example, the fittings of PVP/PCA 10:1 and 2:1 are displayed in 
Figure 5.9A.  Rate constants were reduced with the PCA content, ranging from ~1.10 h-1 for PVP/PCA 
10:1 to ~0.04 h-1 for PVP/PCA 2:1, Figure 5.9B. An important drop in the value of k was observed 
between PVP/PCA 7.5:1 and 3.5:1. This phenomenon can be related to a PCA content-dependent 




Figure 5.8 A, B, release profile of PCA from the different PVP/PCA matrices under investigation over 
a period of 72 and 24 hours, respectively. C, D, the release of methylene blue (MB) and carminic acid 
(CA) from PVP/PCA 1:0, 10:1, and 2:1 systems over a period of 72 hours. Insets show the 







Figure 5.9 A, first-order fitting of drug release experiments for PVP/PCA 10:1 and 2:1. The correlation 







5.3.7 Antibacterial assay  
In the hospital environment, among the most common bacterial strains that can cause wound infections 
are S. aureus, and E. coli [277]. These strains can strongly affect the healing in terms of time, cost, and 
compliance of the patients [278, 279]. For this reason, a suitable dressing should be able to ensure a 
well-disinfected wound bed to improve the healing process. In particular, we investigated the 
antibacterial properties of PVP/PCA samples against E.coli and S. aureus. More specifically, PVP/PCA 
1:0, 10:1, 5:1, and 2:1 films were placed on LB agar plates with E.coli and on blood agar plates with S. 
aureus. After 24 hours of growth, an inhibition growth zone increasing in a dose-dependent manner 
was formed, as reported in Figure 5.10 and Table 5.2. On the contrary, no inhibition zone was observed 
in the plates of pure PVP, suggesting that the antibacterial activity occurred due to the PCA release.  
 
 





PVP/PCA Inhibition radius for E. coli Inhibition radius for S. aureus 
1:0 N.D. N.D. 
10:1 0.2 ± 0.1 cm 0.25 ± 0.1 cm 
5:1 0.3 ± 0.05 cm 0.35 ± 0.1 cm 
2:1 0.4 ± 0.1 cm 0.5 ± 0.05 cm 
Table 5.2 Results of antibacterial assays for the PVP/PCA 1:0, 10:1, 5:1, 2:1 samples expressed as a 
radius of the bacteria-free zone 
 
5.3.8. Mice tests 
5.3.8.1. In vivo films application  
We evaluated the in vivo bio re-sorption and biocompatibility of PVP/PCA films. PVP/PCA film 2:1 
and PVP/PCA film 10:1 were applied on the wound and monitored for 48 hours, Figures 11A, B. No 
adverse signs were observed after the application of both types of films. PVP/PCA 10:1 showed a 
regular tendency in film degradation and exudate absorption. In the first 4 hours, almost 50% of the 
starting material was reabsorbed. Six hours after application, PVP/PCA 10:1 film was completely 
disappeared. On the other hand, PVP/PCA 2:1 film displayed a similar tendency with PVP/PCA 10:1 
film in the first two hours. After this time, PVP/PCA 2:1 absorbed exudate and swelled until 6 hours 
when it started to disappear and was eventually reabsorbed 24 hours after the application. The slower 
reabsorption of PVP/PCA 2:1 with respect to PVP/PCA 10:1 can ensure the prolonged release of PCA 
and higher covering time for the wound.   
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5.3.8.2 MMP-9 measurement by Western blot 
Matrix metallopeptidases (MMPs) are present in wounds and are key elements of inflammation, 
epithelial repair, and resolution: excessive MMPs are a feature of chronic wounds, with patients more 
prone to infections and ulcers, while regulation of MMP levels could lead to improved wound healing 
[280, 281]. MMPs expression is very low in normal skin, but their levels increase after injury. In the 
first phase of wound healing, MMPs are secreted by inflammatory cells and facilities cleaning of 
wound bed while in the second phase the MMPs play an important role in the formation of new 
granulation tissue which leads to re-epithelization [282]. Among MMPs, MMP9 is the main regulator 
and exerts multiple roles during different phases of wound healing [282, 283].In order to verify the 
activity of PCA, the presence of the metalloproteinase MMP-9, which is normally increased in 
wounded mice, was investigated [284, 285]. Figure 5.12A shows a high MMP-9 immunoreactivity in 
the skin of wounded mice of the sham group. The expression of MMP-9 was significantly reduced in 
mice treated with PVP/PCA 2:1 film, whereas there was no change in expression between sham group 
and PVP/PCA 10:1 film group, Figures 5.12A and 5.12B. One possible explanation could be that 
despite PVP PCA 10:1 film is absorbed faster, the amount of p-coumaric acid is not enough to develop 
any anti-inflammatory response. On the other hand, the modulation by PCA/PVP 2:1 sample of MMP-




Figure 5.11 A, representative pictures showing different wounds treated with PVP/PCA 2:1 and 10:1 
films. B, PVP/PCA 2:1 and 10:1 reabsorption profiles percentage as function of time (***p < 0.0001, n 





Figure 5.12 A, percentage expression of MMP-9 protein in naïve, sham, PVP/PCA 2:1, and PVP/PCA 
10:1 mice. B, Western blot analysis of MMP-9 protein in naïve, sham, PVP/PCA 2:1 and PVP/PCA 
10:1 mice. The blot is representative of 3 different analyses and illustrates the MMP-9 protein 
expression in mouse wounded skin. GAPDH was used as internal control. Protein weights are 
expressed in kDa. 
 
5.4 Conclusions 
This chapter showed that significant amounts of a dietary phenolic compound, PCA, can be blended 
with PVP in ethanol solutions. After drop-casting and evaporation of the solvent, transparent, free-
standing films were obtained in the form of miscible solid dispersions, as confirmed by XRD. Both 
components strongly interacted by H-bonds, originating a new network of these secondary interactions 
that modified the physical properties of the final materials. Thus, PCA showed a role as a plasticizer 
reducing the glass transition temperature and changing the mechanical behavior of the biopolymer 
matrix from rigid to ductile. Resistance to water dissolution was also increased due to the interaction 
between the polar groups of PVP and the phenolic acid compound, resulting in more hydrophobic and 
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waterproof materials. In addition, the blends were highly antioxidant because of the presence of PCA, 
as demonstrated in vitro. Moreover, these films showed good antibacterial activity against common 
pathogens such as E. coli and S. aureus. On model mice wounds, a reduction of the levels of MMP-9, 
related to an anti-inflammatory response, was observed in samples with high concentrations of PCA. 
These results indicate that these biopolymer composites can be promising materials for the treatment of 

























6.1 Contributions of this thesis 
This dissertation has contributed to the area of biomedicine and bioengineering by exploring and 
studying novel scalable solutions in fabrication and design of PVP-based biomedical devices for 
treatment of different type of wounds, taking in account all the modern features required for the 
production of smart and effective wound dressings.  
A new formulation for the dispersion of the antibiotic Ciprofloxacin in a matrix of PVP using the acetic 
acid in the form of transparent and flexible films avoiding crystals formation inside the materials was 
obtained. A plasticizer effect on the polymer matrix by the Ciprofloxacin and acetic acid was observed. 
Moreover, electrospun PVP/Cipro/acetic acid-based nanofibers starting from an aqueous solution with 
a diameter between 250-400 nm were produced. The biocompatibility, the drug release and penetration 
into the skin, and the antibacterial efficacy against P. aeruginosa of the PVP/Cipro/acetic acid-based 
films and nanofibers were tested on an infected-wound model based on ex-vivo human skin, resulting 
in suitable for the treatment of biofilms infected wounds. 
A novel multifunctional bilayer construct for the sequential delivery of a local disinfectant, and an 
antibiotic was produced by scalable water-based methods with the possibility of large size samples 
preparation. The multifunctional bilayer construct showed self-adhesion to human skin, water 
absorption capacity, antibacterial activity against three different strains, biocompatibility, no hemolytic 
effects, and anti-inflammatory properties in vitro. Moreover, it was tested in an in-vivo full-thickness 
excisional wound healing mice model, and it can be totally-resorbed by the wound, accelerate the 
wound closure and reduce the level of cytokines, suggesting that this material can be considered a 
useful tool in case of burns and chronic wounds. 
The facile fabrication of a new bio-composite based on PVP and the phenolic compound p-coumaric 
acid was described. p-Coumaric acid strongly affected the PVP properties regarding interaction and 
dissolution in water, antioxidant activity, and mechanical properties. The PVP/PCA system ensured a 
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prolonged release not only of the p-coumaric acid but also of other model drugs dispersed in the bio-
composite.  Moreover, the films showed total resorption of the materials and a reduction of the levels 
of matrix metallopeptidases 9, when tested in an in-vivo full-thickness excisional wound healing mice 
model, indicating a potential application for the treatment of chronic wounds.  
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Valentini, P. P. Pompa, R. Spanò, L. Goldoni, R. Bertorelli, A. Athanassiou, I. S. Bayer. 4
th
 
International Conference on Biomedical Polymers and Polymeric Biomaterials, July, 15 – 18, 2018, 
Krakow, Poland. 
 
Oral Presentation: Transparent Ciprofloxacin-polyvinylpyrrolidone antibiotic films and nanofiber mats 
as potential skin and wound care dressings; M. Contardi, J. A. Heredia-Guerrero, G. Perotto, P. 
Valentini, P. P. Pompa, R. Spanò, L. Goldoni, R. Bertorelli, A. Athanassiou, I. S. Bayer. 10th 
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on p-Coumaric Acid for Controlled Release, Journal of Materials Chemistry B 2019 (In press)  
http://dx.doi.org/10.1039/C8TB03017K 
 
M. Contardi, D. Russo, G. Suarato, J. A. Heredia-Guerrero, L. Cesaracciu, I. Penna, N. Margaroli, M. 
Summa, R. Spanò, G. Tassistro, L. Vezzulli, T. Bandiera, R. Bertorelli, A. Athanassiou, I. S. Bayer; 
Polyvinylpyrrolidone/Hyaluronic acid-based Bilayer Constructs for Sequential Delivery of 
Cutaneous Antiseptic and Antibiotic, Chemical Engineering Journal (2019) 358, 912-923. 
 
M. Contardi, J. A. Heredia-Guerrero, G. Perotto, P. Valentini, P. P. Pompa, R. Spanò, L. Goldoni, R. 
Bertorelli, A. Athanassiou, I. S. Bayer; Transparent ciprofloxacin-povidone antibiotic films and 
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6.3 Recommendations for future work 
In an attempt to further evaluate PVP-based materials for controlled release and wound treatment the 
following are potentially valuable suggestions for future work. PVP-Cipro-acetic acid films could test 
in the infected ex-vivo human-skin model against S. aureus or a polymicrobial infection. The 
accelerated wound closure mediated by the bilayer construct could be evaluated with histological 
analysis. Moreover, the anti-inflammatory activity of this material could also be evaluated and 
characterized by a burn mice model. Finally, the wound closure rate of the PVP/PCA could be tested to 
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